

Needle Syringe Program National Minimum Data Collection



2021 National Data Report

Needle Syringe Program National Minimum Data Collection

NATIONAL DATA REPORT 2021

Prepared by
Ms Sue Heard, Dr Jenny Iversen, Ms Louise Geddes, Dr Jisoo Amy Kwon, Professor Lisa Maher
The Kirby Institute, UNSW Sydney
November 2021

© Kirby Institute

ISSN 2652-9270

This publication is available at: <http://www.kirby.unsw.edu.au>

Kirby Institute
UNSW Sydney
Sydney NSW 2052
Australia

Telephone: 02 9385 0900 Facsimile: 02 6100 2860 International prefix: 612 Email: info@kirby.unsw.edu.au

Suggested citation: Heard S, Iversen J, Geddes L, Kwon JA and Maher L. Needle Syringe Program National Minimum Data Collection: National Data Report 2021. Sydney: Kirby Institute, UNSW Sydney; 2021.

The Needle Syringe Program National Minimum Data Collection project is funded by the Australian Government Department of Health. Kirby Institute, Faculty of Medicine, UNSW Sydney.

Acknowledgements

We would like to acknowledge the many people who have assisted with the development and implementation of the NSP NMDC project.

The project received support and input from the following members of the NSP NMDC Reference Group in 2021: Ms Jenny Taleski (ACT); Ms Kate Patten (NSW); Mr David Decolongon (NT); Mr Robert Kemp (QLD); Mr Stephen Lymb and Mr Bruce Surman (SA); Ms Myf Briggs (TAS); Mr Gary Morris and Ms Terrie Spall (VIC); Ms Jude Bevan (WA); Ms Melanie Walker and Ms Lauren Bradley (Australian Injecting and Illicit Drug Users League); Mr Sione Crawford (Harm Reduction Victoria); Mr Charles Henderson and Dr Mary Ellen Harrod (NSW Users and AIDS Association).

We also appreciate the valuable assistance provided by Ms Stephanie Stephens, (ACT), Mr Benet Brogan (QLD), Ms Kendall Robertson (SA), Mr Rob Knight (VIC), Ms Teneille Wisby and Mr David Worthington (WA), and NSP attendees and staff and managers at NSP services.

Ethical approval for this project was obtained from the UNSW Human Research Ethics Committee-A. Formal written permission to access jurisdictional data was sought and obtained from state and territory Health Departments.

The Needle Syringe Program National Minimum Data Collection (NSP NMDC) is funded by the Australian Government Department of Health.

Acronyms

ABS	Australian Bureau of Statistics
ACT	Australian Capital Territory
ANSPS	Australian Needle Syringe Program Survey
ASGS	Australian Statistical Geography Standard
ATS	Amphetamine-type stimulants
BBV	Blood-borne viral
GAM	UNAIDS Global AIDS Monitoring
GCCSA	Greater Capital City Statistical Area
NSP	Needle syringe program
NSP NMDC	Needle syringe program national minimum data collection
NSW	New South Wales
NT	Northern Territory
QLD	Queensland
OOS	Occasions of service
SA	South Australia
SA1(2,3,4)	Statistical Area 1(2,3,4)
SDM	Syringe dispensing machine
PIEDS	Performance and image enhancing drugs
PWID	People who inject drugs
STI	Sexually transmitted infections
TAS	Tasmania
UNAIDS	Joint United Nations Programme on HIV/AIDS
VIC	Victoria
WA	Western Australia

Table of Contents

Acknowledgements	i
Acronyms	ii
List of Tables and Figures	iv
Summary	1
1. Introduction	3
2. NSP Services	4
3. Service Provision	12
4. Needle and Syringe Distribution	21
5. Future Directions	28
6. References	29
Appendix A: Methodological Notes	31
Appendix B: National and Jurisdictional Tables	36
Glossary	63

List of Tables

- Table 2.1 Number of NSP services nationally by type, 2008 and 2016-2021
- Table 4.1 National syringe distribution and per capita syringes distributed, 2011/2012-2020/2021
- Table 4.2 National syringe distribution per PWID*, 2011/2012-2020/2021
- Table A.1 National lifetime and recent (past 12 months) injection of illicit drugs (%) among people aged 14 years or older, 2001-2019
- Table A.2 National number of illicit drug arrests, 2005/06-2019/20
- Table A.3 National number of illicit drug seizures, 2005/06-2019/20
- Table A.4 National number of accidental deaths due to opioids among those aged 15-54 years, 2005-2019
- Table A.5 Age standardised rate of opioid-related hospital separations per million persons aged 10-59 years, 2005/06-2018/19
- Table A.6 Number of new diagnoses of hepatitis C virus infection among people aged 15-24 years, 2005/06-2019/20
- Table B.x.1 Needle and syringe distribution by public and pharmacy sector, 2011/2012–2020/2021
- Table B.x.2 NSP outlet type and method by public and pharmacy sector, 2017-2021
- Table B.x.3 Occasion of service-level data, 2017-2021

List of Figures

- Figure 2.1 National NSP services (%) by outlet type in 2021
- Figure 2.2 Jurisdictional NSP services (%) by outlet type in 2021
- Figure 2.3 National number of public sector NSPs providing take-home naloxone access programs in 2021
- Figure 2.4 National NSPs (%) by outlet type and greater capital city statistical area in 2021
- Figure 2.5 National NSPs (%) by outlet type and remoteness area in 2021
- Figure 2.6 National number of NSPs by outlet type and SA3 in 2021
- Figure 2.7 National total number of NSP outlets by SA3 in 2021
- Figure 3.1 National OOS in 2017-2021
- Figure 3.2 National OOS (%) by age group in 2017-2021
- Figure 3.3 National proportion female (%) by age group in 2017-2021
- Figure 3.4 National OOS (%) by Indigenous status in 2017-2021
- Figure 3.5 National OOS drug injected (%) by ABS Drugs of Concern Broad Groups in 2017-2021
- Figure 3.6 National OOS drug injected (%) by ABS Drugs of Concern Broad Groups and Base Groups in 2017-2021
- Figure 3.7 National OOS among young people (aged <25 years) and older people (aged ≥50 years) by gender and drug injected in 2021
- Figure 3.8 National NSP OOS health education interventions in 2017-2021
- Figure 3.9 National NSP OOS referral destination in 2017-2021
- Figure 4.1 National needle and syringe distribution by public and pharmacy sector NSP, 2017-2021 by quarter
- Figure 4.2 National needle and syringe distribution by public and pharmacy sector NSP, 2011/12-2020/21
- Figure 4.3 Per capita needle and syringe distribution, 2011/12-2020/21
- Figure 4.4 National syringe coverage per PWID*, 2011/12-2020/21
- Figure 4.5 Frequency of injection among ANSPS respondents (%), 2011-2020
- Figure 4.6 Mid-point, upper and lower estimates of the proportion of injections covered by a sterile syringe among PWID*, 2011/12-2020/21
- Figure A.1 Relative changes in PWID indicators 2004/05-2019/20
- Figure A.2 Trends in the estimated number of people who inject drugs on a regular basis in Australia 2000/01-2020/21
- Figure B.x.1 Total number of NSP outlets by SA3 in 2021

Summary

All Australian states and territories operate needle syringe programs (NSPs), providing a range of services to people who inject drugs (PWID). NSPs are a key component of current and previous National Strategies designed to reduce blood-borne viral infections and their associated morbidity, mortality, and personal and social impacts.

NSP services

Since 2017, all jurisdictions have operated the full range of NSP outlet types, with a total of 4,218 NSPs in operation nationally in 2021.

The NSP NDMC collates data on the number of NSP outlets operating on 30 June at the end of each reporting period. Australia's combined network of jurisdictional NSP services comprised 106 primary, 800 secondary and 2,913 pharmacy NSPs in June 2021. These face to face services were supplemented by 399 syringe dispensing machines (SDMs).

As in previous years, there were minor changes to the number of NSP outlet types in all jurisdictions. Over the past five years (2017 to 2021) the number of primary and secondary NSPs remained relatively stable, however the number of SDMs increased by one quarter and pharmacy NSPs increased by around one fifth over this timeframe.

There was an increase in all outlet types between 2008 and 2021, including a 25% increase in the number of primary NSPs (from 85 in 2008 to 106 in 2021), a 7% increase in the number of secondary outlets (from 745 in 2008 to 800 in 2021),

and a 51% increase in the number of pharmacy NSPs (from 1,934 in 2008 to 2,913 in 2021). Notably the number of SDMs operating in Australia more than tripled, from 118 in 2008 to 399 in 2021 with all jurisdictions providing SDMs since 2018.

The number of public sector NSPs with programs to facilitate access to take-home naloxone increased from 66 in 2019 to 189 in 2021.

In 2019, the NSP NDMC Reference Group endorsed the collection of data on the number of public sector NSPs providing programs to facilitate access to take home naloxone. In addition to an increase in the number of NSPs providing take-home naloxone programs, the number of jurisdictions providing these programs increased from five in 2019 to eight in 2021.

Service provision

Based on data collected in February 2021, an estimated 2,000 occasions of service were provided per day at primary and secondary NSPs.

Data on occasions of service (OOS) were collected in late February 2021. The estimated number of OOS at primary and secondary NSPs was in decline by around 5% per annum between 2017 and 2020, but an accelerated decline in OOS was observed in 2021 due to the impact of COVID-19 pandemic. This acceleration was not unexpected, as NSPs encouraged clients to ensure they had sufficient supplies of injecting equipment to

withstand the possibility of COVID-19 disruptions, including lockdowns^{1,2}.

Overall, there was a 30% decline in the estimated annual OOS observed over the last five years, from 765,000 in 2017 to 525,000 in 2021.

Two in five public sector NSP OOS involved provision of a health education intervention and one in ten OOS involved a referral within or to an external agency in 2021.

Two thirds (64%) of NSP attendees at public sector NSP services on the 2021 snapshot day were aged between 30 and 49 years of age. Young people (aged less than 25 years) comprised 3% of NSP attendees, while older people (aged 50 years or above) comprised 22% of NSP attendees. Almost three in four (72%) NSP attendees were male. Excluding OOS where Indigenous status was not reported, 21% of NSP attendees identified as Aboriginal and/or Torres Strait Islander.

Stimulants and hallucinogens (44%) (predominantly methamphetamine) were the most commonly reported drugs injected on the snapshot day in 2021, followed by analgesics (heroin, other opioids and opioid substitution therapies, 37%) and anabolic agents and selected hormones (predominantly anabolic steroids, 9%). Stimulants and hallucinogens were also the most commonly reported drugs injected among young people (39%), while analgesics were the most commonly reported drugs injected among older people (51%).

Needle and syringe distribution

In 2020/21, 50.2 million needles and syringes were distributed in Australia.

There was a 13% decrease in needle and syringe distribution in 2020/21 compared to the previous twelve-month period (July 2019 to June 2020). Notwithstanding this annual decline, there was a 2% increase in needle and syringe distribution over the five-year period 2016/17 to 2020/21 and a 24% increase over the ten-year period from 2011/12 to 2020/21. Although the per capita needle and syringe distribution among the Australian population aged 15-64 years increased over the past decade (from 2.7 syringes in 2011/12 to 3.0 in 2020/21), there was a 3% decline in per capita syringe distribution observed over the past 5 years and a 14% decline in 2020/21 compared to 2019/20.

In 2020/21, 50.2 million syringes were distributed to an estimated population of 74,327 people who regularly inject drugs in Australia, the equivalent of 675 each per annum, exceeding the UNAIDS definition of high syringe coverage (>200 syringes per PWID per annum) by more than three-fold. Syringe coverage, defined as the proportion of all injections (administered by people who regularly inject drugs) covered by a sterile syringe was 121% in 2020/21.

In 2021, the Australian Government Department of Health and the Kirby Institute formalised an agreement to extend implementation of the Needle Syringe Program National Minimum Data Collection project until November 2024.

1. Introduction

Needle syringe programs (NSPs) have been in operation in Australia since 1986 and are a key component of current and previous National Strategies for reducing blood borne viral (BBV) infections and sexually transmitted infections (STIs)^{3,4}. The National Strategies aim to reduce the transmission of HIV, hepatitis B and hepatitis C, and STIs and to reduce associated morbidity, mortality and personal and social impacts. It is important to monitor progress towards aims outlined in the National Strategies, including indicators related to evidence-based prevention programs, such as NSPs⁵. NSPs are also a key element of the harm reduction framework outlined in the National Drug Strategy⁶.

NSPs provide a range of services that aim to reduce the harms associated with injection drug use, including prevention of BBVs through provision of sterile injecting equipment and safer sex materials. Injecting equipment provided by NSPs primarily includes sterile needles and syringes and containers for the safe disposal of used injecting equipment and may also include other injection equipment such as alcohol swabs and ampoules of sterile water. NSPs also provide information and education, referral to a range of health and welfare services and some NSPs provide programs to facilitate access to take-home naloxone.

All eight Australian states and territories operate NSP services and collect a range of operational data, including i) agency-level administrative data, ii) service provision and iii) needle and syringe distribution data. Commencing in 2016⁷, this sixth annual NSP NMDC report provides a national summary of data elements in the NSP NMDC Data Dictionary⁸ and a descriptive overview and summary data of NSP services in each jurisdiction.

The NSP NMDC also contributes to reporting against key indicators outlined in the National BBV and STI Surveillance and Monitoring Plan 2018-2022 that accompanies Australia's National HIV and National Hepatitis C Strategies and UNAIDS Global AIDS Monitoring (GAM)⁹. Indicators are a) Number of needles and syringes distributed per person who injects drugs per year (National BBV and STI Surveillance and Monitoring Plan 2018-2022 and GAM 2020) and b) Proportion of injections covered by a sterile syringe in the previous calendar year (National BBV and STI Surveillance and Monitoring Plan 2018-2022).

It is anticipated that NSP NMDC reports will also be used for service monitoring and planning which will benefit the community of people who inject drugs (PWID) and provide public health benefits to the Australian population.

2. NSP Services

NSP outlet type

In Australia, NSP services are available through a range of outlet types. The NSP NMDC Data Dictionary 2019v4⁸ provides the following definitions for NSP outlet type.

Primary NSPs are dedicated to the provision of services to PWID. Primary NSPs dispense a wide range of sterile injecting equipment, offer needle syringe disposal services, provide information and education on a range of issues relating to injection drug use and have the capacity to make referrals to other health and welfare services as required.

Secondary NSPs operate within existing health or community services with staff that are not solely dedicated to the provision of services to PWID. Secondary NSPs may provide the same range of services as primary NSPs but typically have a limited capacity to deliver specialist services other than the dispensing of sterile injecting equipment and the provision of disposal facilities, although not all secondary outlets provide disposal facilities.

Pharmacy NSPs are community retail pharmacies that dispense needles and syringes to PWID. This includes free dispensing as part of a subsidised scheme, as well as supply of injecting equipment on a commercial basis. Community pharmacies that

independently supply needles and syringes (where there is no association with a state/territory NSP scheme) are not included in the NSP NMDC as there is no way to determine whether syringes are provided to PWID or solely provided to people with medical conditions (for example for IVF treatment).

Syringe dispensing machines (SDMs) provide sterile injecting equipment via vending machines or dispensing chutes. SDMs dispense needles and syringes at no cost or for a small fee and typically operate in locations and at times when other NSP services are unavailable.

The NSP NMDC counted the number of NSPs as the total of primary + secondary + pharmacy + SDMs. If a primary or secondary NSP outlet also operated a SDM these were counted as separate NSPs for the purpose of the NSP NMDC. For example, a fixed site secondary outlet with two SDMs outside the building was counted as 1 x secondary and 2 x SDM.

In June 2021, there were 4,218 NSPs operating nationally (Figure 2.1) and all jurisdictions operated the full range of NSP outlet types. Pharmacy NSPs were the most common outlet type nationally (n=2,913, 69%) and in all jurisdictions (Figure 2.2). Of the 1,305 public sector outlets operating nationally in 2021, 800 were secondary NSPs, 399 were SDMs

and 106 were primary NSPs. Although there were significantly fewer primary outlets compared to secondary and pharmacy outlets, the comprehensive nature of services provided by primary

NSPs offers opportunities for PWID to access health care and other services that are crucial to the prevention and treatment of BBVs and the reduction of drug-related harms to individuals and communities.

Figure 2.1 National NSP services (%) by outlet type in 2021





Figure 2.2 Jurisdictional NSP services (%) by outlet type in 2021



Primary and secondary NSPs predominantly operate as fixed site services, although 11 primary and 10 secondary NSPs operate as outreach services without a fixed site. A substantial proportion (n=56, 53%) of primary NSPs operate multiple modes of service delivery, including a combination of fixed site, mobile, outreach, peer distribution and/or SDM services.

SDMs ensure after-hours access to sterile needles and syringes. All jurisdictions operated SDMs in 2021, with 399 SDMs in use nationally, including approximately 220 secondary outlets that operate SDMs. SDMs predominantly dispense combined 1ml needles and syringes, although a small minority of SDMs dispense larger volume syringes and detachable needles. Two thirds of Australian SDMs (67%) dispensed needles and syringes at no cost to the consumer in 2021. Among the remaining SDMs, the majority (98%) required a consumer payment of between AUD \$2 and \$4.

There was a 46% increase in the total number of NSP outlets over the 13-year period 2008-2021 (Table 2.1). The NSP NDMC collates data on the number of NSP

outlets operating on 30 June at the end of each reporting period. As in previous years, there were minor changes to the number of NSP outlet types in all jurisdictions. There was an increase in all outlet types between 2008 and 2021, including a 25% increase in the number of primary NSPs (from 85 in 2008 to 106 in 2021), a 7% increase in the number of secondary outlets (from 745 in 2008 to 800 in 2021), and a two-fold increase in the number of pharmacy NSPs (from 1,934 in 2008 to 2,913 in 2021). Notably the number of SDMs operating in Australia more than tripled, from 118 in 2008 to 399 in 2021 with all jurisdictions providing SDMs since 2018.

Since the inaugural NSP NMDC report in 2016⁵, there has been a 20% increase in the total number of NSPs operating in Australia (from 3,509 in 2016 to 4,218 in 2021). The number of primary (102 in 2016 to 106 in 2021) and secondary NSPs (786 in 2016 to 800 in 2021) were relatively stable over the past six years. However, there were notable increases among both pharmacy NSPs of 26% (2,321 in 2016 to 2,913 in 2021) and SDMs of 33% (300 in 2016 to 399 in 2021).


Table 2.1 Number of NSP services nationally by type, 2008 and 2016-2021

	2008 ¹⁰	2016	2017	2018	2019	2020	2021
Primary NSP	85	102	98	101	98	104	106
Secondary NSP	745	786	784	774	908	811	800
SDM	118	300	323	344	340	377	399
Pharmacy	1,934	2,321	2,422	2,458	2,836	2,867	2,913
Total	2,882	3,509	3,627	3,677	4,182	4,159	4,218

Take-home naloxone is designed to assist in the management of opioid overdose. In February 2016, the Australian Therapeutic Goods Administration changed the listing of naloxone from Schedule 4 (prescription only) to Schedule 3 (pharmacist over the counter) access. Take-home naloxone programs¹¹ are gradually being scaled in Australia and for the third year, this report provides data on the number of public-sector NSPs with programs to facilitate

access to take-home naloxone. As of 30 June 2021, take-home naloxone programs were available in all jurisdictions through 189 public sector NSPs (Figure 2.3), a three-fold increase over the period 2019 to 2021 (n=66 in 2019) and a 12% increase over the past year (n=166 in 2020). Almost three-quarters of primary NSPs (73%, n=77) and 14% of secondary NSPs (n=112) had programs to facilitate access to take-home naloxone in 2021.

Figure 2.3 National number of public sector NSPs providing take-home naloxone access programs in 2021




Geographic coverage

The ABS ASGS Greater Capital City Statistical Areas (GCCSA)¹² are designed to represent a socio-economic definition of each of the eight state and territory capital cities. This means the greater capital city boundary includes people who regularly socialise, shop or work within the city, but who live in the small towns and rural areas surrounding the city. It does not define the built-up edge of the city. There are eight regions representing each of the Australian state and territory capital cities and eight regions covering the rest of each

state and territory. There is only one GCCSA for the ACT and one for the Other Territories of Jervis Bay, Christmas Island and Cocos (Keeling) Islands.

The majority of primary (n=69, 65%) and pharmacy (n=1,745, 60%) NSP outlets are located within greater capital city boundaries, whereas the majority of secondary NSP outlets (n=620, 78%) and SDMs (n=275, 69%) are located in the rest of each state (Figure 2.4).

Figure 2.4 National NSPs (%) by outlet type and greater capital city statistical area in 2021



Note: Location data not available for all services in one jurisdiction


The Australian Bureau of Statistics (ABS) Australian Statistical Geography Standard (ASGS)¹³ provides a geographical standard for the publication of statistics by relative remoteness. The Australian Remoteness Areas categories are 0) Major Cities, 1) Inner Regional, 2) Outer Regional, 3) Remote, 4) Very Remote, 5) Migratory/Offshore/Shipping.

As shown in Figure 2.5, the mix of NSP outlet types varied according to geographic region by remoteness area. Approximately two thirds (n=1,893, 65%) of Australia's 2,913 pharmacy NSPs were located in major cities with pharmacies comprising the majority (82%) of NSP outlets in this ASGS area. Pharmacy NSPs were also the most common NSP outlet type in inner regional (n=625, 61%) and outer regional (n=372, 51%) areas, however significantly fewer pharmacy NSPs were located in remote (n=35, 27%)

and very remote (n=6, 9%) areas of Australia. Conversely, the proportion of secondary outlets increased with remoteness area, with secondary outlets the most common NSP outlet type in remote (n=66, 53%) and very remote (n=49, 73%) areas. Similarly, the proportion of SDMs increased with remoteness area, with two thirds (n=254, 64%) of Australia's 399 SDMs located outside major cities.

The ASGS¹³ Statistical Area 3 (SA3) provides a regional breakdown of Australia with 340 SA3s nationally (excluding non-spatial SA3 special purpose codes). The majority (96%) of SA3 in Australia have at least one NSP outlet. Figures 2.6 and 2.7 provide visual representations of the geographic coverage of primary, secondary, pharmacy and SDM NSP outlets by SA3 in Australia in 2021.

Figure 2.5 National NSPs (%) by outlet type and remoteness area in 2021



Note: Location data not available for all services in one jurisdiction

Figure 2.6 National number of NSPs by outlet type and SA3 in 2021





Figure 2.7 National total number of NSP outlets by SA3 in 2021

3. Service Provision

NSP occasions of service

All jurisdictions collect client-level OOS data. Data collection varies according to outlet type with limited capacity at secondary outlets and no capacity at SDMs or pharmacy NSPs. In 2015, the NSP NMDC National Reference Group agreed on four client-level OOS data elements (age, gender, Indigenous status and drug injected) and two service-level OOS data elements (health education/interventions and referrals provided) for inclusion in the NSP NMDC.


The NSP NMDC Data Dictionary⁸ defines a NSP occasion of service (OOS) as contact between NSP staff and a NSP client in order to transact sterile injecting equipment, advice or other related service from a NSP. The Data Dictionary provides a framework for reporting each of the NSP NMDC client-level and service-level OOS data elements.

Jurisdictional client-level OOS data were collected on a nominated snapshot day during the last week of February in all years. It should be noted that client-level OOS data were not collected from every NSP outlet in some jurisdictions and that client level data were unavailable for a small number of OOS in all years 2017 to 2021 (range n=59-81).

Nationally, there were 1,953 occasions of service (OOS) recorded at participating

public sector NSPs in Australia on the nominated snapshot day in February 2021. This equates to an estimated 525,000 OOS provided by public sector NSP services in 2021, the lowest number of OOS observed in any year since the NSP NMDC project commenced in 2016. As shown in Figure 3.1 the estimated number of OOS at primary and secondary NSPs was in decline by around 5% per annum between 2017 and 2020, but an accelerated decline in OOS was observed in 2021. This acceleration was not unexpected, as NSPs encouraged clients to ensure they had sufficient supplies of injecting equipment to withstand the possibility of COVID-19 disruptions, including lockdowns. Overall, there was a 30% decline in the estimated annual OOS observed over the last five years, from 765,000 in 2017 to 525,000 in 2021.

Figure 3.1 National OOS in 2017-2021




Age

The NSP NMDC Data Dictionary⁸ defines age according to the ABS Age Standard¹⁴ as AGE10P (age of the NSP client in single years). All jurisdictions collected 'age' as a data element in 2021. Most jurisdictions collected age in single years (AGE10P), however two jurisdictions collected age group and the minimum data available to report in the NSP NMDC is ten-year age groups (AGE10P). It should also be noted that there was minor misalignment with AGE10P and the age group categories collected in one jurisdiction and some adjustment of data was necessary (see Appendix A: Methodological Notes).

Two in three (64%) OOS at public sector NSPs on the 2021 snapshot day involved NSP attendees aged 30-49 years (35% aged 40-49 years and 29% aged 30-39 years). One in five (22%) OOS involved

NSP attendees who were aged 50 years or older and one in ten (11%) involved NSP attendees aged 20-29 years. Less than one percent of OOS involved attendees aged less than 20 years. Young people (aged less than 25 years) comprised three percent (n=68) of OOS at public sector NSPs nationally in 2021. As shown in Figure 3.2, based on the ABS AGE10P grouping, over the period 2017 to 2021 significant increases were observed in the proportion of attendees aged 40-49 years (p-trend=0.005) and those aged 50+ years (p-trend<0.001). Conversely, significant declines were observed in the proportion of NSP attendees aged 20-29 years (p-trend<0.001) and those aged 30-39 years (p-trend=0.003). The age breakdown of NSP attendees according to ABS AGE10P was stable for participants aged less than 20 years.

Figure 3.2 National OOS (%) by age group in 2017-2021




Gender

The NSP NMDC Data Dictionary⁸ defined gender as per the 2016 ABS Standard for Sex and Gender Variables¹⁵ which states gender is the distinction between male, female, and genders which are a combination of male and female, or neither male nor female, as reported by the client. All jurisdictions collected gender in 2021, with most jurisdictions (n=5) collecting this data element according to the 2016 ABS standard where permissible values were: 1) Male, 2) Female and 3) Other. It is noted that a new ABS Standard for ‘Sex, Gender, Variations of Sex Characteristics and Sexual Orientation Variables’ was released on 14 January 2021¹⁶. The NSP NMDC Data Dictionary⁸ will be revised to align with the new ABS standard.

Consistent with previous years, on the snapshot day in 2021, three quarters (72%) of NSP OOS recorded involved male NSP attendees and one quarter of NSP OOS recorded involved females. Five NSP OOS (<1%) recorded on the snapshot day in 2021 involved people who identified their gender as ‘other’.

Females comprised between one fifth and one third of NSP attendees in all age groups in all years 2017 to 2021, except among NSP attendees aged <20 years, where the proportion of females ranged from 18% in 2017 to 38% in 2020. The proportion of females in all age groups was stable over the period 2017 to 2021 (Figure 3.3).

Figure 3.3 National proportion female (%) by age group in 2017-2021



Indigenous status


The NSP NMDC Data Dictionary⁸ uses the ABS Indigenous Status Standard¹⁷, which defines Indigenous status as “Whether a person identifies as being of Aboriginal or Torres Strait Islander origin.”

The permissible values are: 1) Aboriginal but not Torres Strait Islander origin, 2) Torres Strait Islander but not Aboriginal origin, 3) Both Aboriginal and Torres Strait Islander origin, 4) Neither Aboriginal nor Torres Strait Islander origin. Seven of the eight jurisdictions currently collect client-level OOS data on Indigenous status, although data collection is not aligned to the ABS standard in one of these jurisdictions. The minimum reporting in the 2021 NSP NMDC is Indigenous status as

a binary response; ‘Yes, Aboriginal and/or Torres Strait Islander origin’ or ‘Neither Aboriginal nor Torres Strait Islander origin’.

Among the seven jurisdictions where client-level OOS data on Indigenous status were collected and excluding OOS where Indigenous status was not reported, 21% (n=315) of NSP OOS on the snapshot day involved NSP attendees who identified as Aboriginal and/or Torres Strait Islander (Figure 3.4). Over the period 2017 to 2021 there was a significant increase in the proportion of attendees who identified as Aboriginal and/or Torres Strait Islander (from 16% in 2017 to 21% in 2021, p-trend<0.001).

Figure 3.4 National OOS (%) by Indigenous status in 2017-2021



Note: One jurisdiction did not collect data on Indigenous status in any years 2017-2021, and one jurisdiction did not collect data on Indigenous status between 2017-2019.

Drugs injected


The NSP NMDC uses the ABS Drugs of Concern Classification¹⁸ Broad and Base level groups to report on the drug/s injected as defined in the NSP NMDC Data Dictionary⁸. The NSP NMDC Data Dictionary⁸ defines drugs injected as the drug (or drug type), as stated by the client. Given differences in existing jurisdictional data collections, this is either the drug the client is intending to inject following the current OOS (three jurisdictions) or the drug last injected by the client on the most recent occasion of injection (four jurisdictions). One jurisdiction does not currently collect client-level OOS data on drug/s injected.

Figure 3.5 illustrates the breakdown of drugs injected by NSP attendees on the nominated snapshot day between 2017

and 2021 according to ABS Drugs of Concern Broad Groups. Stimulants and Hallucinogens were the most commonly reported class of drugs injected for the fourth consecutive year in 2021 (n=675, 44%), followed by Analgesics (n=566, 37%) and Anabolic Agents and Selected Hormones (n=135, 9%). Injecting more than one drug subtype was reported at 5% (n=74) of OOS at public sector NSPs nationally in 2021.

Over the period 2017 to 2021, a significant increase was observed in the proportion of NSP attendees who reported Stimulants and Hallucinogens as the class of drugs injected (p-trend<0.001) and a concurrent decrease in those who reported Analgesics (p-trend<0.001).

Figure 3.5 National OOS drug injected (%) by ABS Drugs of Concern Broad Groups in 2017-2021




Note: One jurisdiction did not collect data on drug injected in any years 2017-2021

Five jurisdictions collected data that aligned with the ABS Drugs of Concern Base level definitions (n=1,267 in 2021). Heroin (n=244, 49%) was the most commonly reported drug injected by NSP clients in the 'Analgesics' category, while methamphetamine (n=448, 84%) was the most commonly reported drug injected in

the 'Stimulants and Hallucinogens' category (see Figure 3.6). In 2021, other performance and image enhancing drugs (PIEDs, (n=51, 43%) were the most commonly reported drug injected in the 'Anabolic Agents and Selected Hormones' category.

Figure 3.6 National OOS drug injected (%) by ABS Drugs of Concern Broad Groups and Base Groups in 2017-2021



Note: Among the five jurisdictions that collected ABS Drugs of concern at Base level units

Young people

Among n=64 young people (aged less than 25 years) attending NSPs on the snapshot day in 2021 and excluding the jurisdiction that did not collect data on drugs injected, Stimulants and Hallucinogens were the most commonly reported drug class last injected, reported by 39% of young people in 2021. This was followed by Anabolic Agents and Selected Hormones (27%) and Analgesics (23%). Five percent of young people reported injecting other drugs or more than one drug subtype and 6% did not report drug injected.


Men accounted for 69% of OOS involving a young person in 2021. Men comprised 60% of young people who injected Analgesics, 48% of those who injected Stimulants and Hallucinogens and 100% of those who injected Anabolic Agents and Selected Hormones (Figure 3.7).

Older people

The NSP NMDC defines older people as those aged 50 years and older. Among n=372 OOS involving older people on the snapshot day in 2021 and excluding the jurisdiction that did not collect data on drugs injected, 51% reported injecting Analgesics, 39% reported injecting Stimulants and Hallucinogens and 2% reported injecting Anabolic Agents and Selected Hormones. Three percent of older people reported injecting more than one drug and 5% did not report the drug injected.

Consistent with previous years, men comprised the majority (73%) of OOS that involved older people. Men comprised 70% of older people who injected Analgesics, 81% of those who injected Stimulants and Hallucinogens and 67% of those who injected Anabolic Agents and Selected Hormones (Figure 3.7).

Figure 3.7 National OOS among young people (aged <25 years) and older people (aged ≥50 years) by gender and drug injected in 2021




Health education/interventions provided

A health education/intervention is defined as the provision of information, education or a brief intervention to a client by NSP staff at an occasion of service. Given some inconsistency in the way this data element is currently collected in jurisdictions, the NSP NMDC uses a two-level hierarchical structure to collate health education/intervention(s) into broad groups. It should also be noted that not all secondary NSP services have the capacity to provide a range of health education/interventions to PWID who attend their services.

Where detailed data on health education/intervention were available, data were recoded into the five broad groups defined in the NSP NMDC Data Dictionary⁸: 1) BBV and STI, 2) Drug health, 3) Other health, 4) Other non-health and 5) Peer-based.

Among NSP services that collected data on the provision of health education/interventions, two in five (40%) OOS at public sector NSPs included the provision of a health education/intervention. This was slightly lower than the 45% of OOS that included provision of health/education interventions in 2020. As shown in Figure 3.8, one in two (n=329, 49%) health education interventions related to BBVs and STIs (including safer injection practices and vein care) in 2021, a decline from 63% in 2017 (p-trend<0.001). One in five OOS included the provision of other health education/interventions (n=155, 23%), an increase from 8% in 2020. One in ten OOS involved more than one health (n=79, 12%) or other non-health (n=75, 11%) education/interventions, while 5% (n=36) were related to drug health education/interventions in 2021.

Figure 3.8 National NSP OOS health education interventions in 2017-2021



Referrals


Primary and secondary NSP services also provide attendees with referrals to a range of health, welfare, legal and other agencies. The NSP NMDC Data Dictionary⁸ defines referral as “The type of service or agency to which a client is referred during a NSP service contact.”

As with health education/interventions and described previously, the NSP NMDC uses a two-level hierarchical structure to collate referrals due to some inconsistency in the way this data element is currently collected at the jurisdictional level. The hierarchical structure of this data element enables recoding of existing jurisdictional data into broad groups. Although all jurisdictions collect this data element, a minority of secondary NSP services have the capacity to provide or collect referral data.

The NSP NMDC project recoded referral data into the following five broad groups: 1) BBV and STI, 2) Drug health, 3) Other health, 4) Other non-health and 5) Peer-based.

Of the NSP services that recorded data on referrals on the snapshot day in 2021, one in ten (n=139, 9%) OOS at public sector NSPs involved the provision of a referral. Approximately one in three (n=48, 35%) referrals were made to BBV and STI services, while one in three (n=41, 30%) were made to other health services and one in six (n=22, 16%) were made to drug health services. Smaller proportions of referrals were made to other non-health services (n=16, 12%) or peer-based services (n=1, 1%). Multiple referrals were provided on one in twenty (n=9, 7%) NSP OOS that involved a referral. Figure 3.9 shows the national NSP OOS referral destination in 2017 to 2021.

Figure 3.9 National NSP OOS referral destination in 2017-2021



4. Needle and Syringe Distribution


The NSP NMDC used the NSP NMDC Data Dictionary⁸ definition for ‘Needles and syringes distributed’ which includes a description of 1) combined needle and syringe, 2) syringe without needle and 3) needle without syringe. Because injection requires both a needle and a syringe, the Data Dictionary guide states “the total number of needles and syringes is obtained using the calculation: ‘Combined needle and syringe’ + ‘syringe without needle’ to avoid double counting”.

The NSP NDMC reports needle and syringe distribution by financial year. This report covers the period July 2020 to June 2021, during the global COVID-19 pandemic. Known pandemic impacts on needle and syringe distribution include a) stockpiling of injecting equipment following the declaration of a global pandemic in

March 2020, b) encouragement of clients to procure sufficient quantities of injecting equipment to withstand COVID-19 public health measures, such as lock downs and c) modifications to NSP operating procedures to ensure social distancing².

As shown in Figure 4.1, public sector needle and syringe distribution was inflated in the January to March quarter of 2020 largely due to stockpiling that resulted from concerns regarding the potential for COVID-19 disruptions to supply chains and/or service delivery. Quarterly needle and syringe distribution was subsequently stable over the period April 2020 to July 2021, albeit at ~12.5 million needles and syringes distributed per quarter, around one million lower than the ~13.8 million distributed per quarter in 2019.


Figure 4.1 National needle and syringe distribution by public and pharmacy sector NSP, 2017-2021 by quarter



In 2020/21, 50.2 million needles and syringes were distributed nationally in Australia (Figure 4.2). Although this represents a 13% decrease compared to the previous twelve-month period (July 2019 to June 2020), there was a 2% increase in needle and syringe distribution

over the five-year period 2016/17 to 2020/21 and a 24% increase over the ten-year period from 2011/12 to 2020/21. In 2020/21, the public and pharmacy sectors dispensed 44.0 million (88%) and 6.1 million (12%) needles and syringes respectively.

Figure 4.2 National needle and syringe distribution by public and pharmacy sector NSP, 2011/12-2020/21



Per capita needle and syringe distribution

Per capita needle and syringe distribution was calculated by dividing the number of needles and syringes distributed by the Australian population aged 15-64 years. The denominator excluded children (aged less than 15 years) and older people (65 years and older) as injection drug use is less prevalent in these age groups. Calendar year ABS population data was converted to financial year by calculating the mean of the population estimate in


consecutive calendar years. The per capita rate of needles and syringes distributed nationally increased by 12% over the ten-year period from 2011/12-2020/21, however there was a 3% decline over the five-year period from 2016/17 to 2020/21 and a 14% decline between 2019/20 and 2020/21 (Table 4.1 and Figure 4.3). In 2020/21, 3.0 needles and syringes were distributed per person aged 15-64 years.

Table 4.1 National syringe distribution and per capita syringes distributed, 2011/12-2020/21

Year	Needle and syringe distribution (millions)			Per capita needles/syringes
	Public	Pharmacy	Total	
2011/12	35.2	5.1	40.3	2.7
2012/13	37.4	4.8	42.3	2.8
2013/14	38.5	5.2	43.6	2.8
2014/15	39.0	5.6	44.6	2.8
2015/16	42.9	6.5	49.5	3.1
2016/17	42.5	6.6	49.1	3.1
2017/18	42.4	6.6	49.0	3.0
2018/19	46.4	6.3	52.8	3.2
2019/20	51.1	6.6	57.8	3.5
2020/21	44.0	6.1	50.2	3.0

Notes: Denominator for per capita needles and syringes is the population aged 15-64 years.

Totals may not add up due to rounding

Figure 4.3 Per capita needle and syringe distribution, 2011/12-2020/21

Note: Denominator for per capita needles and syringes is the population aged 15-64 years.

Syringe distribution per PWID

UNAIDS Global AIDS Monitoring includes 'needles and syringes distributed per person who injects drugs' as one of the key indicators for reporting on the global AIDS response⁹. UNAIDS defines syringe coverage as 'low' (<100 syringes per PWID per annum), 'medium' (100-200 syringes per PWID per annum) and 'high' (>200 syringes per PWID per annum)¹⁹. In addition, the World Health Organization Global Health Sector Strategy on Viral Hepatitis, 2016–2021²⁰ has set a target of 300 syringes per PWID per annum by 2030.

Building on previous methods used to estimate the Australian PWID population size²¹, a method to generate annual estimates of the PWID population size was developed by Kwon and colleagues²².


PWID were defined as people who had injected drugs in the previous 12 months and included people who inject drugs on a regular basis (defined as people who had injected for at least 12 months, an average of 10 times per month, with injecting in most months) and people who inject drugs occasionally (defined as people who injected at least once in the last 12 months, but not frequently enough to be considered a person who injects drugs on a regular basis).

As in previous years, the NSP NMDC used a range of annually updated data sources to estimate trends in the size of the Australian population of people who inject drugs on a regular basis (see Methodological Notes, Appendix A).

There were an estimated 74,327 people who inject drugs on a regular basis in Australia in 2020/21 and this population was stable over the past decade (Table 4.2). The mean number of syringes per PWID was calculated by dividing the number of syringes distributed by the estimated number of people who inject drugs on a regular basis in each financial year. As shown in Figure 4.4, although there was a 24% increase in syringes distributed per PWID between 2011/12 and 2020/21, the number of syringes per PWID declined by 13% between 2019/20 and 2020/21. In 2020/21 an estimated 675 syringes were distributed per person who injects drugs on a regular basis, the equivalent of 1.8 syringes per day and exceeding the UNAIDS definition of high syringe coverage by three-fold.

Table 4.2 National syringe distribution per PWID*, 2011/12-2020/21

Year	Number of people who inject on regular basis*	Syringes distributed (millions)	Syringes per PWID*
2011/12	73,942	40.3	545
2012/13	73,995	42.3	571
2013/14	74,042	43.6	589
2014/15	74,084	44.6	602
2015/16	74,123	49.5	667
2016/17	74,158	49.1	661
2017/18	74,251	49.0	660
2018/19	74,277	52.8	710
2019/20	74,303	57.8	777
2020/21	74,327	50.2	675

Figure 4.4 National syringe coverage per PWID*, 2011/12-2020/21

Note: * Syringes per PWID includes people who inject on a regular basis and excludes those who inject occasionally

Syringe coverage per injection

Although the calculation of the mean number of syringes distributed per PWID is a useful tool to monitor trends over time, it does not take frequency of injection into account. Additional analyses were conducted to assess the extent to which demand for sterile syringes was met. Data on frequency of injection was obtained from the Australian NSP Survey²³ and the methodology described in Kwon et al²². estimated the number of sterile syringes required to cover all injections among people who inject drugs on a regular basis (assuming one sterile syringe was used per injection).

The following assumptions were used: injection >3 times per day required a mean of 5 (range 4-6) syringes per day, injection 2-3 times per day required a mean of 2.5

(range 2-3) syringes per day, injection once per day required one syringe per day, injection more than weekly but not daily required a mean of 3.5 (range 2-60) syringes per week and injection monthly but not weekly required a mean of 0.5 (range 0.3-0.9) syringes per week.

As shown in Figure 4.5, there were some changes in the frequency of injection reported among Australian NSP Survey respondents in 2020. Notably, injection frequency was lower, with a decline in the proportion of respondents who reported injecting more than once per day and a concomitant increase in the proportion of respondents who reported injecting less than daily, while the proportion of respondents who reported injecting once per day was stable.

Figure 4.5 Frequency of injection among ANSPS respondents (%), 2011-2020





Figure 4.6 shows the mid-point and lower/upper syringe coverage estimates over the period 2011/12 to 2020/21. Syringe coverage was 100% or higher in all years 2011/12 to 2020/21. It is important to note that syringe coverage of greater than 100% is required to accommodate syringes utilised by people who inject drugs occasionally and syringes that are not used for an injection (for example drawing up needles/syringes, wastage, failed injection attempts or stockpiling).

Despite a decline in the number of OOS and the number of needles and syringes distributed in Australia in 2020/21 (525,000 and 50.2 million respectively) compared to 2019/20 (665,000 and 57.8 million respectively), syringe coverage per injection among the population of people who inject drugs on a regular basis remained high at 121% in 2020/21. Although this represents a 5% decline in syringe coverage compared to 2019/20 (127%), syringe coverage was likely artificially inflated in 2019/20 due to stockpiling of syringes that occurred when COVID-19 was declared a global pandemic in March 2020 (see Figure 4.1).

Figure 4.6 Mid-point, upper and lower estimates of the proportion of injections covered by a sterile syringe among PWID*, 2011/12-2020/21



Note: * Syringe coverage among people who inject on a regular basis (excluding those who inject occasionally)

5. Future Directions

This is the sixth annual National Data Report for the NSP NMDC project. The NSP NMDC Data Dictionary developed in 2017 was updated in 2019 to reflect improvements in national alignment and provides the framework national alignment of NSP NMDC data elements. The Data Dictionary will likely be updated to reflect the ABS 'Standard for Sex, Gender, Variations of Sex Characteristics and Sexual Orientation Variables' released in early 2021¹⁶ following consultation with the NSP NMDC Reference Group.

Historical data (from 2008) were used to assess past decade temporal trends in the number and type of NSP services (Section 2). The collation of historical data also enabled the presentation of past decade temporal trends in needle and syringe distribution (Section 4). Since 2019, the NSP NMDC has included data on the provision of programs to facilitate access to take-home naloxone (Section 2).

Alignment of data collected in jurisdictions has improved for several data elements, most notably in relation to client-level OOS data elements (Section 3, Service provision). The NSP NMDC project and key stakeholders were aware of misalignment in multiple data elements when the NSP NMDC data elements were agreed in 2015. Data elements that remain misaligned are discussed in Methodological Notes at Appendix A.

The NSP NMDC Reference Group will continue to provide input into the feasibility and practicality of collecting and reporting additional elements, for example the extent to which ancillary injecting equipment is provided through NSP services and the potential for additional disaggregation of needle and syringe distribution by provider type as outlined in the recent UNAIDS Global AIDS Monitoring 2020 framework.

In 2021, the Australian Government Department of Health and the Kirby Institute formalised an agreement to extend implementation of the Needle Syringe Program National Minimum Data Collection project until November 2024.

6. References

1. Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, Ryan J, Hall M, Ezard N, Haber P, Lintzeris N, Maher L. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. *Harm Reduction Journal* 2020;17(1):26.
2. Iversen J, Sabin K, Chang J, Morgan Thomas R, Prestage G, Strathdee S.A. and Maher L. (2020), COVID-19, HIV and key populations: Cross-cutting issues and the need for population-specific responses. *Journal of the International AIDS Society* 23(10):e25632. <https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25632>
3. Australian Government Department of Health and Ageing (2018). *Eighth National HIV Strategy 2018–2022*. Commonwealth of Australia, Canberra, Australia. [https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1/\\$File/HIV-Eight-Nat-Strategy-2018-22.pdf](https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1/$File/HIV-Eight-Nat-Strategy-2018-22.pdf)
4. Australian Government Department of Health and Ageing (2018). *Fifth National Hepatitis C Strategy 2018–2022*. Commonwealth of Australia; Canberra, Australia. [https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1/\\$File/Hep-C-Fifth-Nat-Strategy-2018-22.pdf](https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1/$File/Hep-C-Fifth-Nat-Strategy-2018-22.pdf)
5. Australian Government Department of Health and Ageing (2020). *National Blood-borne Viruses and Sexually Transmissible Infections Surveillance and Monitoring Plan 2018-2022*. Commonwealth of Australia; Canberra, Australia. [https://www1.health.gov.au/internet/main/publishing.nsf/Content/AE05C032DDCB7533CA257BF00020AAC4/\\$File/Surveil-Monit-Plan-2018-2022-Nat-BBV-STI.pdf](https://www1.health.gov.au/internet/main/publishing.nsf/Content/AE05C032DDCB7533CA257BF00020AAC4/$File/Surveil-Monit-Plan-2018-2022-Nat-BBV-STI.pdf)
6. Australian Government Department of Health (2017). *National Drug Strategy 2017–2026*. Commonwealth of Australia; Canberra, Australia. https://www.health.gov.au/sites/default/files/national-drug-strategy-2017-2026_1.pdf
7. Iversen J, Linsen S, Kwon JA, and Maher L (2017). *Needle and Syringe Program National Minimum Data Collection: National Data Report 2016*. Sydney: Kirby Institute, UNSW Sydney. https://kirby.unsw.edu.au/sites/default/files/kirby/report/NSP-NMDC_Report-2017.pdf
8. The Kirby Institute (2019). *Needle Syringe Program National Minimum Data Collection: Data Dictionary 2019.v4*. Sydney: The Kirby Institute, UNSW Sydney. https://kirby.unsw.edu.au/sites/default/files/kirby/report/NSP-NMDC_Data-Dictionary-2019.pdf
9. UNAIDS (2019). *Global AIDS Monitoring 2020, Indicators for monitoring the 2016 United National Political declaration on ending AIDS*. UNAIDS: Geneva Switzerland. https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf
10. Wilson DP, Kwon A, Anderson J, Thein R, Law M, & Maher L (2009). *Return on investment 2: Evaluating the cost-effectiveness of needle and syringe programs in Australia*. Australian Government Department of Health and Ageing; Canberra, Australia.

11. Australian Government Department of Health (2019). *Take home naloxone pilot*. <https://www.health.gov.au/initiatives-and-programs/take-home-naloxone-pilot>.
12. Australian Bureau of Statistics (2016). *Australian Statistical Geography Standard (ASGS) 1270.0.55.001, Volume 1, Main Structure and Greater Capital City Statistical Areas, July 2016*. Commonwealth of Australia: Canberra, Australia.
13. Australian Bureau of Statistics (2011). *Australian Statistical Geography Standard (ASGS) 1270.0.55.005, Volume 5, Remoteness Structure, July 2011*. Commonwealth of Australia: Canberra, Australia.
14. Australian Bureau of Statistics (2014). *Age Standard, 1200.0.55.006, Version 1.7, March 2014*. Commonwealth of Australia: Canberra, Australia.
15. Australian Bureau of Statistics (2016). *Standard for Sex and Gender Variables, 1200.0.55.012, February 2016*. Commonwealth of Australia: Canberra, Australia.
16. Australian Bureau of Statistics (2020). *Standard for Sex, Gender, Variations of Sex Characteristics and Sexual Orientation Variables, January 2021*. Commonwealth of Australia: Canberra, Australia.
17. Australian Bureau of Statistics (2014). *Indigenous Status Standard, 1200.0.55.008, Version 1.5, October 2014*. Commonwealth of Australia: Canberra, Australia.
18. Australian Bureau of Statistics (2011). *Australian Standard Classification of Drugs of Concern. Cat no. 1248.0*. Commonwealth of Australia: Canberra, Australia.
19. WHO & UNODC & UNAIDS. (2012). *Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users (revision)*. Geneva, Switzerland. https://apps.who.int/iris/bitstream/handle/10665/77969/9789241504379_eng.pdf?ua=1
20. World Health Organization (2016). *Global health sector strategy on viral hepatitis 2016–2021*. Geneva, Switzerland <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/>
21. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, Law M. et al. (2007). Modelling the hepatitis C virus epidemic in Australia. *Drug Alcohol Depend* 91(2-3), 228-235.
22. Kwon JA, Iversen J, Law M, Dolan K, Wand H, Maher L. (2019). Estimating the number of people who inject drugs and syringe coverage in Australia, 2005-2016. *Drug Alcohol Depend* 197, 108-114.
23. Heard S, Iversen J, & Maher L. (2021). *Australian Needle Syringe Program Survey National Data Report 2016-2020: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees*. Sydney: Kirby Institute, UNSW Sydney. <https://kirby.unsw.edu.au/report/australian-nsp-survey-national-data-report-2016-2020>

Appendix A: Methodological Notes

Data collection

The following data were provided by each state and territory Health Department:

- 1) Agency-level administrative data, including outlet type and location of all NSPs operating at 30 June 2021.
- 2) Demographic and drug use data for attendees at public sector (primary and secondary) NSPs on a snapshot day February in 2021.
- 3) Quarterly needle syringe distribution data by public and pharmacy sector.

Ethical approval for the NSP NMDC was obtained from the UNSW Sydney Human Research Ethics Committee-A. Formal written permission to access jurisdictional data was sought and obtained from state and territory Health Departments.

Data analysis

Data coding, cleaning and analysis was conducted using Microsoft Excel, version 2007 (Build 13029.20344, Microsoft Office 365 Apps for enterprise (Microsoft Corporation, Redmond WA) and Stata/IC version 14.2 (StataCorp LP, College Station TX).

In 2021, geocoding of NSP outlet locations used street address, suburb, postcode and state to obtain latitude, longitude and SA1. Concordance tables from the ABS and Australian Government Department of Health determined RA, GCCSA, SA2, SA3, SA4 and Primary Health Network based on the SA1 values.

Data comparison notes and limitations

The data presented in the sixth annual NSP NMDC are subject to limitations and data may need to be converted from financial to calendar year for external reporting. Although overall alignment and completion of NSP NMDC data elements was high in 2021, exceptions are highlighted below.

Some jurisdictions use additional categories to describe the NSP outlet type (for example 'Enhanced Primary' and 'Enhanced Secondary'). In consultation with the relevant jurisdictions and in line with recommendations from the NSP NMDC Reference Group, these NSPs were recoded to the most appropriate 'primary' or 'secondary' definition.

The count of NSPs comprised the total of primary + secondary + pharmacy + SDMs. Where NSP outlets also had SDM(s) these were counted as separate NSPs for the purpose of the NSP NMDC. Historical data on the number of NSPs was obtained from NSP Return on Investment 2 report¹⁰.

Age group categories were not aligned with ABS AGE10P or young people (aged <25 years) in two jurisdictions in 2017 and one jurisdiction in all subsequent years. Data was adjusted, on a proportional basis using age distributions from remaining jurisdictions. These adjustments may have resulted in a slight over-estimate of the proportion of young people.

One jurisdiction did not collect data on Indigenous status in any years (2017 to 2021), and one jurisdiction did not collect data on Indigenous status between 2017 to 2019. Five jurisdictions collected data as per the ABS definition, while one jurisdiction collected Indigenous status as a binary yes/no. One jurisdiction did not collect data on drug injected in any years 2017 to 2021. Two jurisdictions collected drug injected where data aligned with ABS Drugs of Concern Broad Groups but did not align with Base Groups.

The capacity for secondary NSP outlets to provide health education interventions and referrals may be limited and secondary outlets do not generally collect this information. One jurisdiction provided collated quarterly data for health education interventions and referrals and an estimate of the mean number of daily health education interventions and referrals was generated. It should also be noted that NSP services provide a range of health education interventions to a wide range of external agencies and to the general community. Not all interventions are included in the NSP NMDC minimum data elements, as agreed by the project Reference Group, and are beyond the scope of this report.

One jurisdiction provided data on the number of combined needles and syringes plus needles distributed without syringes. This inconsistency would have minimal impact on the total number of needles and syringes distributed or temporal trends in syringe distribution or syringe coverage.

PWID estimates

PWID population size estimates to 2005 were calculated by Razali et al (2007)²¹. The NSP NMDC project used the method described by Kwon et al (2019)²² to estimate relative change in the Australian population of people who inject drugs on a regular basis from 2005 using the following indicators:

- 1) Lifetime and recent (last 12 months) injection of illicit drugs (Table A.1)
- 2) Illicit drug arrests for amphetamine-type stimulants, heroin/other opioids, cocaine and steroids (Table A.2)
- 3) ATS, heroin and steroid seizures (Table A.3)
- 4) Unintentional deaths due to opioids (Table A.4)
- 5) Age-standardised rate of opioid-related hospital separations per million persons aged 10-59 years (Table A.5).
- 6) HCV notifications among 15-24 years (Table A.6)

Given each of these five indicators is an incomplete measure of probable trends in injection drug use, a best estimate was generated using a combined mean of all indicators. This was used to calculate the relative change in injection drug use since 2005, with log function used to obtain a smooth fit of the data (Figure A.1). Estimates of the Australian population of people who inject drugs on a regular basis 2000/01 to 2020/21 are presented in Figure A.2.

Table A.1 National lifetime and recent (past 12 months) injection of illicit drugs (%) among people aged 14 years or older, 2001-2019

	2001	2004	2007	2010	2013	2016	2019
Lifetime inject	1.8	1.9	1.9	1.76	1.5	1.6	1.5
Recent inject	0.6	0.4	0.5	0.43	0.3	0.3	0.3

Source: *National Drug Strategy Household Survey 2020*

Table A.2 National number of illicit drug arrests, 2005/06-2019/20

	'05/06	'06/07	'07/08	'08/09	'09/10	'10/11	'11/12	'12/13	'13/14	'14/15	'15/16	'16/17	'17/18	'18/19	19/20
ATS	11,848	15,216	16,047	16,452	13,982	12,897	16,828	22,189	26,269	35,468	47,625	47,531	44,887	46,437	79,638
Heroin/ opioids	2,249	2,164	2,279	2,693	2,767	2,551	2,714	2,463	2,771	3,227	2,975	2,970	3,029	3,129	3,514
Cocaine	396	699	669	848	1,244	839	995	1,282	1,466	2,092	2,592	3,366	4,325	5,016	5,393
Steroids	67	142	163	214	314	365	511	661	936	1,210	1,297	1,244	1,201	1,264	1,160

Source: *Illicit Drug Data Report, Australian Crime Commission (2005/06-2019/20)*

Table A.3 National number of illicit drug seizures, 2005/06-2019/20

	'05/06	'06/07	'07/08	'08/09	'09/10	'10/11	'11/12	'12/13	'13/14	'14/15	'15/16	'16/17	'17/18	'18/19	19/20
ATS	9,987	13,243	13,097	13,300	10,543	11,212	15,191	21,056	26,805	32,768	39,014	37,351	37,093	38,250	39,204
Heroin	1,298	1,476	1,411	1,691	1,582	1,700	1,758	1,584	1,598	1,914	2,081	1,951	1,977	2,080	2,230
Steroid	58	91	104	113	134	205	208	331	357	529	509	474	448	391	369

Source: *Illicit Drug Data Report, Australian Crime Commission (2005/06-2019/20)*. Note: Includes only those seizures for which a drug weight was recorded.

Table A.4 National number of unintentional deaths due to opioids among those aged 15-54 years, 2005-2019

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Unintentional deaths due to opioids	369	300	356	492	558	603	605	557	597	703	778	859	898	755	709

Source: Chrzanowska, A., Man, N., Sutherland, R., Degenhardt, L., & Peacock, A. (2021). Trends in drug-induced deaths in Australia, 1997-2019. Drug Trends Bulletin Series. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney. Available at https://drugtrends.shinyapps.io/deaths_2019 (accessed 04 November 2021).

Table A.5 Age-standardised rate of opioid-related hospital separations per million persons aged 10-59 years, 2005/06-2018/19

	'05/06	'06/07	'07/08	'08/09	'09/10	'10/11	'11/12	'12/13	'13/14	'14/15	'15/16	'16/17	'17/18	'18/19
Separations	510	600	660	660	690	690	690	680	730	740	770	730	710	690

Source: Man, N., Chrzanowska, A., Sutherland, R., Degenhardt, L. & Peacock, A. (2021). Trends in drug-related hospitalisations in Australia, 1999-2019. Drug Trends Bulletin Series. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney Available at https://drugtrends.shinyapps.io/hospital_separations (accessed 04 November 2021).

Table A.6 Number of new diagnoses of hepatitis C virus infection among people aged 15-24 years, 2005/06-2019/20

	'05/06	'06/07	'07/08	'08/09	'09/10	'10/11	'11/12	'12/13	'13/14	'14/15	'15/16	'16/17	'17/18	'18/19	'19/20
NNDSS	1,711	1,493	1,372	1,309	1,214	1,158	1,150	1,254	1,232	1,159	1,177	1,157	1,090	1,076	1,040

Source: National Notifiable Diseases Surveillance System 2005-2020, Australian Government Department of Health.

Figure A.1: Relative change in PWID indicators, 2004/05-2019/2020





Figure A.2: Trends in the estimated number of people who inject drugs on a regular basis in Australia, 2000/01-2020/21



Appendix B:

National and Jurisdictional Tables

B.1 National

Table B.1.1 Needle and syringe distribution by public and pharmacy sector, 2011/12–2020/21

National	Public	%	Pharmacy	%	Total
2011/12	35,179,620	87%	5,131,160	13%	40,310,780
2012/13	37,446,914	89%	4,837,457	11%	42,284,371
2013/14	38,457,733	88%	5,168,366	12%	43,626,099
2014/15	38,995,375	87%	5,627,125	13%	44,622,500
2015/16	42,925,047	87%	6,533,048	13%	49,458,095
2016/17	42,493,174	87%	6,558,299	13%	49,051,473
2017/18	42,387,670	86%	6,627,160	14%	49,014,830
2018/19	46,442,981	88%	6,309,051	12%	52,752,032
2019/20	51,147,820	89%	6,611,976	11%	57,759,796
2020/21	44,023,877	88%	6,143,990	12%	50,167,867

Note – 2017/18 and 2018/19 data updated in 2020

Table B.1.2 NSP outlet type and method by public and pharmacy sector, 2017-2021

National	2017	2018	2019	2020	2021
NSP outlet type (%)	n=3,627	n=3,677	n=4,182	n=4,159	n=4,218
Primary	98 (3)	101 (3)	98 (2)	104 (3)	106 (3)
Secondary	784 (22)	774 (21)	908 (22)	811 (19)	800 (19)
SDM	323 (9)	344 (9)	340 (8)	377 (9)	399 (9)
Pharmacy	2,422 (67)	2,458 (67)	2,836 (68)	2,867 (69)	2,913 (69)
NSP outlet method (%)					
<i>Public sector NSP[^]</i>	n=1,205	n=1,219	n=1,346	n=1,292	n=1,305
Fixed	862 (72)	858 (70)	988 (73)	893 (69)	884 (69)
Outreach/mobile	47 (4)	56 (5)	65 (5)	74 (6)	91 (7)
SDM free	98 (8)	107 (9)	111 (8)	175 (14)	200 (15)
SDM chute	74 (6)	72 (6)	72 (5)	72 (6)	67 (5)
SDM cost	151 (13)	165 (14)	157 (12)	130 (10)	132 (10)
Peer distribution	23 (2)	23 (2)	23 (2)	23 (2)	23 (2)
Naloxone*	-- --	-- --	66 (7)	169 (18)	189 (21)
<i>Pharmacy sector (fixed)</i>	2,422 (100)	2,458 (100)	2,836 (100)	2,867 (100)	2,913 (100)

[^] Public sector NSPs may have more than one NSP outlet method

-- Not collected

* % denominator = primary + secondary

Table B.1.3 Occasion of service-level data, 2017 to 2021

National Client-level	2017 n=2797	2018 n=2573	2019 n=2512	2020 n=2392	2021 n=1876
Age (%)					
<20 years	18 (1)	26 (1)	18 (1)	12 (1)	8 (<1)
20-29 years	429 (15)	353 (14)	506 (20)	258 (11)	212 (11)
30-39 years	936 (33)	805 (31)	815 (32)	753 (31)	537 (29)
40-49 years	880 (31)	846 (33)	474 (30)	860 (36)	662 (35)
50+ years	475 (17)	481 (19)	383 (15)	466 (19)	421 (22)
Not reported	59 (2)	62 (2)	43 (2)	43 (2)	36 (2)
Aged <25 (%)	174 (6)	141 (5)	98 (4)	93 (4)	68 (3)
Gender (%)					
Male	2081 (74)	1856 (72)	1823 (73)	1743 (73)	1348 (72)
Female	699 (25)	690 (27)	646 (26)	625 (26)	505 (27)
Other	2 (<1)	3 (<1)	5 (<1)	8 (<1)	5 (<1)
Not reported	15 (<1)	24 (<1)	38 (2)	16 (1)	18 (1)
Indigenous status (%)^					
Yes (Aboriginal or TSI or both)	274 (15)	297 (17)	285 (18)	365 (20)	315 (21)
No	1417 (79)	1321 (75)	1170 (73)	1378 (76)	1165 (77)
Not reported	113 (6)	138 (8)	155 (10)	62 (3)	36 (2)
Drug injected (%)^					
Analgesics	821 (41)	750 (40)	589 (35)	645 (36)	566 (37)
Stimulants and Hallucinogens	770 (36)	805 (42)	752 (45)	832 (46)	675 (44)
Anabolic agents	178 (9)	148 (8)	127 (8)	156 (9)	135 (9)
Other	117 (6)	89 (5)	109 (6)	99 (5)	74 (5)
Not reported	110 (6)	103 (5)	106 (6)	84 (5)	76 (5)
Service-level					
Health education/intervention (%)^					
Yes	1077 (43)	1029 (42)	1087 (47)	1034 (45)	737 (40)
No	1436 (57)	1422 (58)	1248 (53)	1278 (55)	1086 (60)
Not reported	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)
Health education/intervention type (%)^					
BBV & STI	645 (63)	599 (59)	602 (61)	588 (60)	329 (49)
Drug health	45 (4)	22 (2)	23 (2)	24 (2)	36 (5)
Other health	34 (3)	112 (11)	111 (11)	78 (8)	155 (23)
Other non-health	54 (5)	82 (8)	71 (7)	73 (6)	75 (11)
More than one	250 (24)	194 (19)	175 (18)	240 (24)	79 (12)
Not reported	0 (0)	0 (0)	2 (<1)	0 (0)	2 (<1)
Referral (%)^					
Yes	122 (7)	146 (8)	96 (6)	164 (10)	139 (9)
No	1611 (87)	1643 (91)	1477 (94)	1475 (90)	1334 (91)
Not reported	128 (7)	17 (1)	0 (0)	0 (0)	0 (0)
Referral type (%)^					
BBV & STI	66 (54)	58 (40)	38 (40)	70 (43)	48 (35)
Drug health	9 (7)	12 (8)	12 (13)	27 (16)	23 (17)
Other health	21 (17)	35 (24)	27 (28)	32 (20)	42 (30)
Other non-health	25 (20)	19 (13)	14 (15)	19 (12)	16 (12)
Peer based	1 (1)	14 (10)	3 (3)	5 (3)	1 (1)
More than one	0 (0)	4 (3)	2 (2)	10 (6)	9 (6)
Not reported	0 (0)	4 (3)	0 (0)	1 (1)	0 (0)

^ Not collected in all jurisdictions.

B.2 Australian Capital Territory

Description of NSP services in Australian Capital Territory

The Australian Capital Territory (ACT) has the smallest land area of the eight states and territories and has the second smallest population (~431,000 residents in 2021). Two primary NSPs operate in the ACT, operated by Directions Health Services and providing an extended range of injecting equipment and other support services to people who inject drugs. Services include information and education on issues relating to safe injecting practices and health, and referrals to a range of health and social services, including drug treatment services. Programs to facilitate access to take-home naloxone are available through 3 public sector NSPs (2 primary and 1 secondary) in the ACT. A more limited range of injecting equipment is available through 11 secondary NSPs and 39 pharmacy NSP outlets. There are 8 SDMs in the ACT, located outside health centres. These machines contain '4 packs' (including 4 x sterile 1ml combined needle and syringe, swabs, water, spoons and cotton wool within a safe disposal container), available for \$2 per pack and enabling 24-hour access to sterile injecting equipment. Client-level OOS data are collected at both primary NSPs and some secondary NSPs. Collated monthly data are provided to ACT Health Directorate on a 6-monthly basis.

Table B.2.1 Needle and syringe distribution by public and pharmacy sector, 2011/12–2020/21

ACT	Public	%	Pharmacy	%	Total
2011/12	529,326	87%	81,200	13%	610,526
2012/13	547,748	87%	80,400	13%	628,148
2013/14	529,244	87%	76,800	13%	606,044
2014/15	536,412	89%	63,120	11%	599,532
2015/16	542,772	88%	71,520	12%	614,292
2016/17	756,034	91%	73,440	9%	829,474
2017/18	836,031	92%	71,520	8%	907,551
2018/19	824,076	93%	61,920	7%	885,996
2019/20	867,544	91%	82,320	9%	949,864
2020/21	934,667	91%	96,030	9%	1,030,697

[^] 2016/17 - 2019/20 public sector data includes combined 1ml + syringes as per NSP NMDC Data Dictionary⁸, previous years were combined 1ml only

Table B.2.2 NSP outlet type and method by public and pharmacy sector, 2017-2021

ACT	2017	2018	2019	2020	2021
NSP outlet type (%)	n=48	n=51	n=48	n=55	n=60
Primary	2 (4)	2 (4)	2 (4)	2 (4)	2 (3)
Secondary	8 (17)	9 (18)	9 (19)	10 (18)	11 (18)
SDM	6 (13)	6 (12)	6 (13)	6 (11)	8 (13)
Pharmacy	32 (67)	34 (67)	31 (65)	37 (67)	39 (65)
NSP outlet method (%)					
<i>Public sector NSP[^]</i>	n=16	n=17	n=17	n=18	n=21
Fixed	10 (63)	11 (65)	11 (65)	12 (67)	13 (62)
Outreach/mobile	0 (0)	0 (0)	0 (0)	0 (0)	4 (19)
SDM free	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM chute	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM cost	6 (38)	6 (35)	6 (35)	6 (33)	8 (38)
Peer distribution	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Naloxone*	-- --	-- --	0 (0)	3 (25)	3 (23)
<i>Pharmacy sector (fixed)</i>	32 (100)	34 (100)	31 (100)	37 (100)	39 (100)

[^] Public sector NSPs may have more than one NSP outlet method

-- Not collected

* % denominator = primary + secondary


Figure B.2.1 Total number of NSP outlets by SA3 in 2021

Table B.2.3 Occasion of service-level data, 2017 - 2021

Australian Capital Territory Client-level	2017 n=106	2018 n=109	2019 n=133	2020 n=67	2021 n=58
Age (%)					
<20 years	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)
20-29 years	17 (16)	10 (9)	19 (14)	11 (16)	10 (17)
30-39 years	30 (28)	31 (28)	42 (32)	12 (18)	10 (17)
40-49 years	39 (37)	33 (30)	46 (35)	23 (34)	19 (33)
50+ years	19 (18)	34 (31)	25 (19)	20 (30)	19 (33)
Not reported	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)
Aged <25 (%)	8 (8)	5 (5)	2 (2)	4 (6)	4 (7)
Gender (%)					
Male	73 (69)	81 (74)	103 (77)	47 (70)	44 (76)
Female	33 (31)	28 (26)	30 (23)	20 (30)	14 (24)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Indigenous status (%)					
Yes (Aboriginal or TSI or both)	6 (11)	4 (6)	10 (19)	50 (75)	6 (10)
No	33 (61)	58 (89)	39 (72)	12 (18)	52 (90)
Not reported	15 (28)	3 (5)	5 (9)	5 (7)	0 (0)
Drug injected (%)					
Analgesics	21 (39)	29 (45)	21 (39)	32 (48)	24 (41)
Stimulants and Hallucinogens	9 (17)	24 (37)	24 (44)	22 (33)	14 (24)
Anabolic agents	2 (4)	2 (3)	2 (4)	5 (7)	6 (10)
Other	1 (2)	2 (3)	0 (0)	0 (0)	0 (0)
Not reported	21 (39)	8 (12)	7 (13)	8 (12)	14 (24)
Service-level					
Health education/intervention (%)					
Yes	14 (26)	54 (83)	34 (63)	52 (78)	48 (98)
No	40 (74)	11 (17)	20 (37)	15 (22)	1 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Health education/intervention type (%)^					
BBV & STI	-- --	0 (0)	0 (0)	0 (0)	0 (0)
Drug health	-- --	0 (0)	0 (0)	0 (0)	2 (4)
Other health	-- --	9 (17)	11 (32)	13 (25)	11 (23)
Other non-health	-- --	44 (81)	23 (68)	35 (67)	35 (73)
More than one	-- --	1 (2)	0 (0)	4 (8)	0 (0)
Not reported	-- --	0 (0)	0 (0)	0 (0)	0 (0)
Referral (%)					
Yes	11 (20)	0 (0)	0 (0)	0 (0)	2 (4)
No	43 (80)	54 (100)	54 (100)	67 (100)	47 (96)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Referral type (%)					
BBV & STI	9 (82)	0 (0)	0 (0)	0 (0)	0 (0)
Drug health	1 (9)	0 (0)	0 (0)	0 (0)	1 (50)
Other health	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)
Other non-health	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Peer based	1 (9)	0 (0)	0 (0)	0 (0)	0 (0)
More than one	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

B.3 New South Wales

Description of NSP services in New South Wales

New South Wales (NSW) is the most populous of Australia's eight states and territories, with ~8.1 million people residing in NSW in 2021. NSW Health is responsible for the operation of the NSP via Local Health Districts and non-government organisations. There are 29 primary outlets, 254 secondary outlets, 595 pharmacy NSPs and 274 SDMs in NSW. The extensive network of SDMs (including internal dispensing chutes) are predominantly located in or near community health centres and hospital emergency departments. Cost of injecting equipment at SDMs is typically free or provided at a cost of up to \$4.00. Programs to facilitate access to take-home naloxone are available through 31 public sector NSPs (24 primary and 7 secondary) in New South Wales. Client-level OOS data are collected through the Ministry of Health BRISE funded NSW NSP Enhanced Data Collection (NNEDC) project. The NNEDC collects data from ~50 NSPs, including all primary NSPs and some secondary NSPs over a two-week period in late February/early March. NSP NMDC data elements included in the NNEDC are: age, gender, Indigenous status and drug injected. NSW Health provides collated quarterly data on needle and syringe distribution and health education/interventions and referrals.

Table B.3.1 Needle and syringe distribution by public and pharmacy sector, 2011/12–2020/21

NSW	Public	%	Pharmacy	%	Total
2011/12	9,444,001	85%	1,607,376	15%	11,051,377
2012/13	10,230,040	87%	1,572,380	13%	11,802,420
2013/14	10,743,583	87%	1,554,514	13%	12,298,097
2014/15	11,324,378	89%	1,419,126	11%	12,743,504
2015/16	12,114,913	88%	1,705,015	12%	13,819,928
2016/17	12,189,626	87%	1,744,002	13%	13,933,628
2017/18	12,288,628	87%	1,842,141	13%	14,130,769
2018/19	13,146,005	88%	1,772,934	12%	14,918,939
2019/20	13,812,598	88%	1,809,363	12%	15,621,961
2020/21	13,324,366	90%	1,480,242	10%	14,804,608

Table B.3.2 NSP outlet type and method by public and pharmacy sector, 2017-2021

New South Wales	2017	2018	2019	2020[#]	2021
NSP outlet type (%)	n=1,128~	n=1,092	n=1,168	n=1,145	n=1,152
Primary	30 (3)	31 (3)	32 (3)	29 (3)	29 (3)
Secondary	287 (25)	288 (26)	342 (29)	257 (22)	254 (22)
SDM	240 (21)	233 (21)	231 (20)	269 (23)	274 (24)
Pharmacy	571 (51)	540 (49)	563 (48)	590 (52)	595 (52)
NSP outlet method (%)					
<i>Public sector NSP[^]</i>	n=557	n=552	n=605	n=555	n=557
Fixed	314 (61)	317 (57)	369 (61)	280 (50)	277 (50)
Outreach/mobile	6 (2)	10 (2)	10 (2)	17 (3)	27 (5)
SDM free	87 (16)	85 (15)	91 (15)	156 (28)	171 (31)
SDM chute	74 (12)	72 (13)	72 (12)	72 (13)	67 (12)
SDM cost	79 (19)	76 (14)	68 (11)	41 (7)	36 (6)
Peer distribution	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Naloxone [*]	-- --	-- --	3 (<1)	20 (7)	31 (11)
<i>Pharmacy sector (fixed)</i>	571 (100)	540 (100)	563 (100)	590 (100)	595 (100)

[^] Public sector NSPs may have more than one NSP outlet method

~ Estimate based on 2015/16 data

-- Not collected

* % denominator = primary + secondary

[#] includes temporary changes due to the COVID-19 response


Figure B.3.1 Total number of NSP outlets by SA3 in 2021

Table B.3.3 Occasion of service-level data, 2017-2021

New South Wales	2017	2018	2019	2020	2021
Client-level	n=599	n=495	n=427	n=436	n=336
Age (%)					
<20 years	2 (<1)	2 (<1)	1 (<1)	2 (<1)	1 (<1)
20-29 years	83 (14)	66 (13)	56 (13)	50 (11)	43 (13)
30-39 years	180 (30)	132 (27)	116 (27)	128 (29)	70 (21)
40-49 years	176 (29)	149 (30)	143 (33)	133 (31)	112 (33)
50+ years	135 (23)	116 (23)	86 (20)	107 (25)	93 (28)
Not reported	23 (4)	30 (6)	25 (6)	16 (4)	17 (5)
Aged <25 (%)	32 (5)	25 (5)	15 (4)	24 (6)	9 (3)
Gender (%)					
Male	424 (71)	364 (74)	312 (73)	331 (76)	247 (74)
Female	168 (28)	123 (25)	106 (25)	95 (22)	81 (24)
Other	2 (<1)	2 (<1)	3 (<1)	5 (1)	3 (1)
Not reported	5 (<1)	6 (1)	6 (1)	5 (1)	5 (1)
Indigenous status (%)					
Yes (Aboriginal or TSI or both)	121 (20)	106 (21)	84 (20)	88 (20)	70 (21)
No	454 (76)	357 (72)	319 (75)	334 (77)	259 (77)
Not reported	24 (4)	32 (6)	24 (6)	14 (3)	7 (2)
Drug injected (%)					
Analgesics	309 (52)	237 (48)	198 (46)	193 (44)	165 (49)
Stimulants and Hallucinogens	176 (29)	145 (29)	130 (30)	136 (31)	99 (29)
Anabolic agents	55 (9)	54 (11)	49 (11)	74 (17)	45 (13)
Other	34 (6)	20 (4)	15 (4)	22 (5)	18 (5)
Not reported	25 (4)	39 (8)	35 (8)	11 (3)	9 (3)
Service-level					
Health education/intervention (%)					
Yes	327 (55)	240 (48)	208 (49)	211 (49)	171 (51)
No	272 (45)	255 (52)	219 (51)	219 (51)	165 (49)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Health education/intervention type (%)^					
BBV & STI	282 (86)	224 (93)	189 (91)	203 (96)	159 (93)
Drug health	20 (6)	1 (<1)	1 (<1)	1 (<1)	2 (1)
Other health	3 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Other non-health	22 (7)	15 (6)	18 (9)	7 (3)	10 (6)
More than one	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)		0 (0)
Referral (%)					
Yes	66 (11)	76 (15)	31 (7)	65 (14)	54 (16)
No	533 (89)	419 (85)	396 (93)	396 (86)	282 (84)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Referral type (%)					
BBV & STI	34 (52)	36 (47)	15 (48)	43 (66)	29 (54)
Drug health	5 (8)	8 (11)	3 (10)	6 (9)	10 (19)
Other health	11 (17)	15 (20)	6 (19)	8 (12)	6 (11)
Other non-health	16 (24)	17 (22)	7 (23)	8 (12)	9 (17)
Peer based	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
More than one	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

B.4 Northern Territory

Description of NSP services in Northern Territory

The Northern Territory has the third largest land area of Australia's eight states and territories but has the smallest population at ~246,000 residents in 2021. There are 3 primary outlets, 10 secondary outlets, 16 pharmacy NSPs and 6 SDMs. All of the primary NSP outlets are operated by the Northern Territory AIDS and Hepatitis Council (NTAHC) and provide a broad range of injecting equipment alongside information, support and referral services for PWID and facilities for the safe disposal of used injecting equipment. Programs to facilitate access to take-home naloxone are available through 2 public sector primary NSPs in the NT. Secondary and pharmacy-based outlets typically provide a limited range of sterile injecting equipment and disposal facilities. SDMs were introduced in late 2016 and injecting equipment is accessed through tokens which are obtained free of charge from NSP services in the NT or from packs previously obtained from a SDM. Non-identifiable client-level and service-level OOS data are collected at all primary and most secondary NSP services in the NT and line-item data are provided to NT Government Department of Health on a monthly basis.

Table B.4.1 Needle and syringe distribution by public and pharmacy sector, 2011/12-2020/21

NT	Public	%	Pharmacy	%	Total
2011/12	388,587	92%	35,163	8%	423,750
2012/13	454,481	93%	32,285	7%	486,766
2013/14	523,915	95%	30,340	5%	554,255
2014/15	533,278	96%	22,560	4%	555,838
2015/16	542,584	95%	27,165	5%	569,749
2016/17	526,591	97%	17,270	3%	543,861
2017/18	458,193	97%	14,619	3%	472,812
2018/19	421,780	98%	9,650	2%	431,430
2019/20	427,534	97%	15,175	3%	442,709
2020/21	361,728	99%	4,710	1%	366,438

Table B.4.2 NSP outlet type and method by public and pharmacy sector, 2017-2021

Northern Territory	2017	2018	2019	2020	2021
NSP outlet type (%)	n=35	n=37	n=40	n=40	n=35
Primary	3 (9)	3 (8)	3 (8)	3 (8)	3 (9)
Secondary	10 (29)	10 (27)	10 (25)	10 (25)	10 (29)
SDM	3 (9)	3 (8)	4 (10)	4 (10)	6 (17)
Pharmacy	19 (54)	21 (57)	23 (58)	23 (58)	16 (46)
NSP outlet method (%)					
<i>Public sector NSP[^]</i>	n=16	n=16	n=17	n=17	n=19
Fixed	13 (81)	13 (81)	13 (76)	13 (76)	13 (68)
Outreach/mobile	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM free	3 (19)	3 (19)	4 (24)	4 (24)	6 (32)
SDM chute	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM cost	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Peer distribution	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Naloxone*	-- --	-- --	3 (18)	3 (18)	2 (15)
<i>Pharmacy sector (fixed)</i>	19 (100)	21 (100)	23 (100)	23 (100)	16 (100)

[^] Public sector NSPs may have more than one NSP outlet method

-- Not collected

* % denominator = primary + secondary


Figure B.4.1 Total number of NSP outlets by SA3 in 2021

Table B.4.3 Occasion of service-level data, 2017-2021

Northern Territory Client-level	2017 n=39	2018 n=47	2019 n=45	2020 n=45	2021 n=33
Age (%)					
<20 years	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
20-29 years	6 (15)	8 (17)	5 (11)	4 (9)	3 (9)
30-39 years	17 (44)	12 (26)	15 (33)	14 (31)	12 (36)
40-49 years	8 (21)	15 (32)	12 (27)	13 (29)	11 (33)
50+ years	8 (21)	12 (26)	13 (29)	13 (29)	7 (21)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
Aged <25 (%)	6 (15)	8 (17)	5 (11)	4 (9)	3 (9)
Gender (%)					
Male	35 (90)	34 (72)	33 (73)	33 (73)	26 (79)
Female	4 (10)	13 (28)	12 (27)	12 (27)	7 (21)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Indigenous status (%)					
Yes (Aboriginal or TSI or both)	6 (15)	8 (17)	12 (27)	17 (38)	13 (39)
No	33 (85)	39 (83)	33 (73)	27 (60)	20 (61)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
Drug injected (%)					
Analgesics	14 (36)	20 (43)	12 (27)	10 (22)	6 (18)
Stimulants and Hallucinogens	14 (36)	19 (40)	23 (51)	22 (49)	21 (64)
Anabolic agents	7 (18)	6 (13)	3 (7)	1 (2)	3 (9)
Other	0 (0)	1 (2)	3 (7)	5 (11)	1 (3)
Not reported	4 (10)	1 (2)	4 (9)	7 (16)	2 (6)
Service-level					
Health education/intervention (%)					
Yes	4 (10)	12 (26)	13 (29)	8 (18)	7 (21)
No	35 (90)	35 (74)	32 (71)	37 (82)	26 (79)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Health education/intervention type (%)^					
BBV & STI	4 (100)	10 (83)	11 (85)	7 (88)	7 (100)
Drug health	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other health	0 (0)	2 (17)	0 (0)	0 (0)	0 (0)
Other non-health	0 (0)	0 (0)	2 (15)	1 (13)	0 (0)
More than one	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Referral (%)					
Yes	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)
No	39 (100)	46 (98)	45 (100)	44 (98)	33 (100)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Referral type (%)					
BBV & STI	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)
Drug health	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other health	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)
Other non-health	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Peer based	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
More than one	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

B.5 Queensland

Description of NSP services in Queensland

Queensland has the second largest land area of Australia's eight states and territories and has the third largest population, with ~5.2 million residents in 2021. Queensland NSP (QNSP) supports a network of 20 primary NSPs, 117 secondary NSPs, 843 pharmacy NSPs and 70 SDMs. QNSP provides sterile injecting equipment, facilitates the safe disposal of used injecting equipment and improves access and referral to drug treatment programs, health care and other health services. SDMs provide sterile injecting equipment at a fixed cost of \$2 per pack. Programs to facilitate access to take-home naloxone are available through 9 public sector primary NSPs in Queensland. The Queensland NSP Minimum Data Set (QMDS) is a state-wide standardised data collection system that provides core data about program activities. QMDS requires the collection of non-identifiable client-level and service-level OOS data at all primary and most secondary NSPs throughout Queensland. Line item OOS data are provided to Queensland Health on a monthly basis and QMDS includes all NSP NMDC data elements.

Table B.5.1 Needle and syringe distribution by public and pharmacy sector, 2011/12-2020/21

QLD	Public	%	Pharmacy	%	Total
2011/12	7,923,815	92%	718,365	8%	8,642,180
2012/13	8,221,400	94%	546,121	6%	8,767,521
2013/14	8,662,985	90%	1,000,650	10%	9,663,635
2014/15	8,213,475	84%	1,545,610	16%	9,759,085
2015/16	8,781,445	81%	2,077,635	19%	10,859,080
2016/17	8,088,324	80%	2,030,975	20%	10,119,299
2017/18	8,454,980	80%	2,145,925	20%	10,600,905
2018/19	9,274,875	80%	2,267,300	20%	11,542,175
2019/20	11,417,580	82%	2,478,125	18%	13,895,705
2020/21	9,123,690	79%	2,411,825	21%	11,535,515

Table B.5.2 NSP outlet type and method by public and pharmacy sector, 2017-2021

Queensland NSP outlet type (%)	2017 n=933	2018 n=962	2019 n=1027	2020 n=1027	2021 n=1050
Primary	18 (2)	19 (2)	19 (2)	19 (2)	20 (2)
Secondary	133 (14)	129 (13)	132 (13)	132 (13)	117 (11)
SDM	48 (5)	62 (6)	63 (6)	63 (6)	70 (7)
Pharmacy	734 (79)	752 (78)	813 (79)	813 (79)	843 (80)
NSP outlet method (%)					
<i>Public sector NSP[^]</i>	n=199	n=210	n=214	n=214	n=207
Fixed	151 (76)	148 (70)	151 (71)	151 (71)	137 (66)
Outreach/mobile	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM free	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM chute	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM cost	48 (24)	62 (30)	63 (29)	63 (29)	70 (34)
Peer distribution	6 (3)	6 (3)	6 (3)	6 (3)	6 (3)
Naloxone*	-- --	-- --	9 (6)	9 (6)	9 (7)
<i>Pharmacy sector (fixed)</i>	734 (100)	752 (100)	813 (100)	813 (100)	843 (100)

[^] Public sector NSPs may have more than one NSP outlet method

-- Not collected

* % denominator = primary + secondary


Figure B.5.1 Total number of NSP outlets by SA3 in 2021

Table B.5.3 Occasion of service-level data, 2017-2021

Queensland Client-level	2017 n=800	2018 n=681	2019 n=644	2020 n=729	2021 n=637
Age (%)					
<20 years	7 (1)	11 (2)	6 (1)	5 (1)	7 (1)
20-29 years	140 (18)	119 (17)	75 (12)	91 (12)	70 (11)
30-39 years	278 (35)	233 (34)	231 (36)	219 (30)	180 (28)
40-49 years	240 (30)	228 (33)	216 (34)	286 (39)	227 (36)
50+ years	131 (16)	87 (13)	106 (16)	125 (17)	143 (22)
Not reported	4 (1)	3 (<1)	10 (2)	3 (<1)	10 (2)
Aged <25 (%)	66 (8)	40 (6)	26 (4)	29 (4)	30 (5)
Gender (%)					
Male	596 (75)	500 (73)	481 (75)	554 (76)	465 (73)
Female	204 (25)	181 (27)	161 (25)	174 (24)	164 (26)
Other	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Not reported	0 (0)	0 (0)	2 (<1)	1 (<1)	7 (1)
Indigenous status (%)					
Yes (Aboriginal or TSI or both)	88 (11)	91 (13)	94 (15)	125 (17)	135 (21)
No	654 (82)	530 (78)	482 (75)	583 (80)	479 (75)
Not reported	58 (7)	60 (9)	68 (11)	21 (3)	23 (4)
Drug injected (%)					
Analgesics	328 (41)	285 (42)	248 (39)	288 (40)	261 (41)
Stimulants and Hallucinogens	311 (39)	282 (41)	271 (42)	305 (42)	269 (42)
Anabolic agents	91 (11)	57 (8)	52 (8)	61 (8)	57 (9)
Other	49 (6)	37 (5)	43 (7)	44 (6)	31 (5)
Not reported	21 (3)	20 (3)	30 (5)	31 (4)	19 (3)
Service-level					
Health education/intervention (%)					
Yes	304 (43)	223 (33)	270 (42)	264 (36)	198 (31)
No	402 (57)	458 (67)	374 (58)	465 (64)	439 (69)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Health education/intervention type (%)[^]					
BBV & STI	213 (70)	163 (73)	216 (80)	125 (47)	96 (48)
Drug health	10 (3)	3 (1)	8 (3)	10 (4)	11 (6)
Other health	13 (4)	10 (4)	15 (6)	27 (10)	41 (21)
Other non-health	28 (9)	18 (8)	19 (7)	20 (8)	28 (14)
More than one	40 (13)	29 (13)	12 (4)	82 (31)	22 (11)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Referral (%)					
Yes	18 (2)	21 (3)	16 (2)	41 (6)	29 (5)
No	658 (82)	660 (97)	628 (98)	688 (94)	608 (95)
Not reported	124 (16)	0 (0)	0 (0)	0 (0)	0 (0)
Referral type (%)					
BBV & STI	5 (28)	8 (38)	6 (38)	13 (32)	9 (31)
Drug health	3 (17)	1 (5)	4 (25)	7 (17)	9 (31)
Other health	8 (44)	7 (33)	2 (13)	7 (17)	5 (17)
Other non-health	2 (11)	0 (0)	2 (13)	9 (22)	5 (17)
Peer based	0 (0)	1 (5)	2 (13)	5 (12)	1 (3)
More than one	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	4 (19)	0 (0)	0 (0)	0 (0)

B.6 South Australia

Description of NSP services in South Australia

South Australia (SA) has the fourth largest land area of Australia's eight states and territories and is the fifth most populous, with ~1.8 million residents in 2021. The 'Clean Needle Program' provides a range of services to people who inject drugs including the distribution of sterile needles and syringes and disposal equipment, the provision of information and education about safer injecting practices and safe disposal practices, and referral to a variety of services such as drug treatment, health, legal, and social services. Programs to facilitate access to take-home naloxone are available through all public sector CNPs (8 primary and 78 secondary) in South Australia. CNP services are provided at a range of sites in metropolitan and regional South Australia with 8 primary outlets, 78 secondary outlets, 294 pharmacy NSPs and 14 SDMs. SDMs dispense packs at a cost of \$2 per pack and provide 24 hr access to sterile injecting equipment. Non-identifiable client-level and service-level OOS data are collected at all primary and most secondary NSPs throughout South Australia. Line item OOS data are provided to SA Health on a monthly basis. OOS data collection in SA includes all NSP NMDC data elements; with Health education/interventions recorded as a binary (yes/no) response.

Table B.6.1 Needle and syringe distribution by public and pharmacy sector, 2011/12-2020/21

SA	Public	%	Pharmacy	%	Total
2011/12	3,152,280	94%	211,752	6%	3,364,032
2012/13	3,303,580	95%	181,500	5%	3,485,080
2013/14	2,987,753	96%	140,700	4%	3,128,453
2014/15	2,948,020	95%	140,400	5%	3,088,420
2015/16	3,598,090	96%	161,800	4%	3,759,890
2016/17	3,765,034	96%	139,900	4%	3,904,934
2017/18	3,634,366	96%	164,500	4%	3,798,866
2018/19	4,063,762	96%	173,700	4%	4,237,462
2019/20	4,100,184	96%	188,900	4%	4,289,084
2020/21	3,423,350	95%	180,200	5%	3,603,550

Table B.6.2 NSP outlet type and method by public and pharmacy sector, 2017-2021

South Australia NSP outlet type (%)	2017 n=289	2018 n=289	2019 n=380	2020 n=380	2021 n=394
Primary	4 (1)	3 (1)	2 (1)	8 (2)	8 (2)
Secondary	81 (28)	82 (28)	84 (22)	77 (20)	78 (20)
SDM	8 (3)	8 (3)	8 (2)	8 (2)	14 (4)
Pharmacy	196 (68)	196~ (68)	286 (75)	287 (76)	294 (75)
NSP outlet method (%)					
<i>Public sector NSP[^]</i>	n=93	n=93	n=94	n=93	n=100
Fixed	85 (91)	84 (90)	85 (90)	84 (90)	85 (85)
Outreach/mobile	3 (3)	4 (4)	4 (4)	4 (4)	4 (4)
SDM free	0 (0)	0 (0)	0 (0)	0 (0)	6 (6)
SDM chute	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM cost	8 (9)	8 (9)	8 (9)	8 (9)	8 (8)
Peer distribution	10 (11)	10 (11)	10 (11)	10 (11)	10 (10)
Naloxone*	-- --	-- --	0 (0)	85 (100)	86 (100)
<i>Pharmacy sector (fixed)</i>	196 (100)	196 (100)	286 (100)	287 (100)	294 (100)

[^] Public sector NSPs may have more than one NSP outlet method

-- Not collected

~ Estimate based on 2017 data

* % denominator = primary + secondary


Figure B.6.1 Total number of NSP outlets by SA3 in 2021

Table B.6.3 Occasion of service-level data, 2017-2021

South Australia	2017	2018	2019	2020	2021
Client-level	n=279	n=279	n=267	n=269	n=226
Age (%)					
<20 years	1 (<1)	1 (<1)	2 (1)	0 (0)	0 (0)
20-29 years	42 (15)	22 (8)	24 (9)	21 (8)	12 (5)
30-39 years	81 (29)	87 (31)	86 (32)	78 (29)	52 (23)
40-49 years	108 (39)	104 (37)	86 (32)	92 (34)	97 (43)
50+ years	44 (16)	60 (22)	68 (25)	68 (25)	62 (27)
Not reported	3 (1)	5 (2)	1 (<1)	10 (4)	3 (1)
Aged <25 (%)	18 (6)	8 (3)	15 (6)	9 (3)	6 (3)
Gender (%)					
Male	211 (76)	192 (69)	178 (67)	167 (62)	154 (68)
Female	67 (24)	86 (31)	87 (33)	102 (38)	71 (31)
Other	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Not reported	1 (<1)	1 (<1)	2 (1)	0 (0)	0 (0)
Indigenous status (%)^					
Yes (Aboriginal or TSI or both)	31 (17)	52 (20)	43 (16)	65 (25)	40 (18)
No	141 (76)	181 (68)	176 (66)	174 (67)	176 (82)
Not reported	14 (8)	33 (12)	48 (18)	19 (7)	0 (0)
Drug injected (%)^					
Analgesics	70 (25)	65 (23)	41 (15)	44 (16)	59 (26)
Stimulants and Hallucinogens	148 (53)	157 (56)	164 (61)	173 (64)	123 (54)
Anabolic agents	16 (6)	16 (6)	16 (6)	8 (3)	14 (6)
Other	17 (6)	17 (6)	22 (8)	19 (7)	13 (6)
Not reported	28 (10)	24 (9)	24 (9)	25 (9)	17 (8)
Service-level					
Health education/intervention (%)^					
Yes	34 (20)	20 (10)	103 (61)	31 (16)	61 (34)
No	140 (80)	181 (90)	66 (39)	164 (84)	121 (66)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Referral (%)^					
Yes	26 (15)	8 (4)	14 (8)	23 (12)	42 (77)
No	147 (85)	193 (96)	155 (92)	172 (88)	140 (23)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Referral type (%)^					
BBV & STI	17 (65)	4 (50)	5 (36)	4 (17)	4 (10)
Drug health	0 (0)	1 (13)	0 (0)	3 (13)	0 (0)
Other health	2 (8)	2 (25)	6 (43)	6 (26)	29 (69)
Other non-health	7 (27)	1 (13)	1 (7)	0 (0)	0 (0)
Peer based	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
More than one	0 (0)	0 (0)	2 (14)	10 (43)	9 (21)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Note: ^Not collected at all sites. Health education/intervention in South Australia collected as Yes/No

B.7 Tasmania

Description of NSP services in Tasmania

Tasmania has the second smallest land area of Australia's eight states and territories, with a resident population of ~540,000 in 2021. NSP services are delivered through a combination of primary, secondary, pharmacy and SDMs. The NSP operates through a wide range of service providers, including community health services, community service organisations, neighbourhood/community houses, Aboriginal health services, regional hospitals, councils, youth organisations and pharmacies. Programs to facilitate access to take-home naloxone are available through 8 public sector NSPs (all 7 primary outlets and one secondary outlet) in Tasmania. There are 7 primary outlets, 19 secondary outlets, 90 pharmacy NSPs and 5 SDMs in Tasmania. Non-identifiable client and service-level OOS data are collected at all primary NSPs and some secondary NSPs in Tasmania. Line item OOS data are provided to the Tasmanian Department of Health and Human Services on a monthly basis. Tasmania does not collect data on the Indigenous status of NSP attendees.

Table B.7.1 Needle and syringe distribution by public and pharmacy sector, 2011/12-2020/21

TAS	Public	%	Pharmacy	%	Total
2011/12	875,950	100%	-	0%	875,950
2012/13	943,280	100%	-	0%	943,280
2013/14	933,160	100%	-	0%	933,160
2014/15	976,980	100%	-	0%	976,980
2015/16	907,670	100%	-	0%	907,670
2016/17	784,230	90%	91,552	10%	875,782
2017/18	743,612	90%	86,280	10%	829,892
2018/19	753,360	89%	90,540	11%	843,900
2019/20	800,090	90%	92,980	10%	893,070
2020/21	650,770	87%	93,380	13%	744,150

- data not available

Table B.7.2 NSP outlet type and method by public and pharmacy sector, 2017-2021

Tasmania	2017	2018	2019	2020	2021
NSP outlet type (%)	n=123	n=110	n=117	n=125	n=121
Primary	6 (5)	8 (7)	7 (6)	7 (6)	7 (6)
Secondary	19 (15)	14 (13)	17 (15)	18 (14)	19 (16)
SDM	3 (2)	6 (5)	7 (6)	6 (5)	5 (4)
Pharmacy	95 (77)	82 (75)	86 (74)	94 (75)	90 (74)
NSP outlet method (%)					
<i>Public sector NSP[^]</i>	n=28	n=28	n=31	n=31	n=31
Fixed	25 (90)	22 (79)	24 (78)	25 (81)	26 (84)
Outreach/mobile	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM free	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM chute	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM cost	3 (10)	6 (21)	7 (23)	6 (19)	5 (16)
Peer distribution	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Naloxone*	-- --	-- --	0 (0)	0 (0)	8 (31)
<i>Pharmacy sector (fixed)</i>	95 (100)	82 (100)	86 (100)	94 (100)	90 (100)

[^] Public sector NSPs may have more than one NSP outlet method

-- Not collected

* % denominator = primary + secondary


Figure B.7.1 Total number of NSP outlets by SA3 in 2021

Table B.7.3 Occasion of service-level data, 2017-2021

Tasmania Client-level	2017 n=99	2018 n=126	2019 n=73	2020 n=86	2021 n=71
Age (%)					
<18 years	3 (3)				
18-24 years	1 (1)				
25-29 years / *<20	12 (12)	2 (2)	0 (0)	0 (0)	0 (0)
30-34 years / *20-29	16 (16)	21 (17)	7 (10)	6 (7)	7 (10)
35-39 years / *30-39	22 (22)	39 (31)	23 (32)	24 (28)	26 (37)
40-44 years / *40-49	16 (16)	37 (29)	28 (38)	29 (34)	21 (30)
45+ years / *50+	25 (25)	24 (19)	14 (19)	27 (31)	16 (23)
Not reported	4 (4)	3 (2)	1 (1)	0 (0)	1 (1)
Aged <25	4 (4)	9 (7)	2 (3)	4 (5)	1 (1)
Gender (%)					
Male	78 (79)	83 (66)	60 (82)	68 (79)	47 (66)
Female	21 (21)	41 (33)	13 (18)	18 (21)	24 (34)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)
Indigenous status (%)					
Yes (Aboriginal or TSI or both)	0 (0)	0 (0)	0 (0)	10 (12)	11 (15)
No	0 (0)	0 (0)	0 (0)	76 (88)	60 (85)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Drug injected (%)					
Analgesics	42 (42)	56 (44)	27 (37)	28 (33)	22 (31)
Stimulants and Hallucinogens	47 (47)	51 (40)	34 (47)	51 (59)	43 (61)
Anabolic agents	0 (0)	3 (2)	1 (1)	2 (2)	0 (0)
Other	3 (3)	7 (6)	8 (11)	5 (6)	5 (7)
Not reported	7 (7)	9 (7)	3 (4)	0 (0)	1 (1)
Service-level					
Health education/intervention (%)					
Yes	5 (7)	70 (56)	22 (30)	22 (26)	31 (44)
No	65 (93)	56 (44)	51 (70)	64 (74)	40 (56)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Health education/intervention type (%)[^]					
BBV & STI	2 (40)	41 (59)	6 (27)	5 (23)	9 (29)
Drug health	2 (40)	7 (10)	3 (14)	3 (14)	2 (6)
Other health	1 (20)	10 (14)	7 (32)	3 (14)	9 (29)
Other non-health	0 (0)	3 (4)	4 (18)	8 (36)	0 (0)
More than one	0 (0)	9 (13)	2 (9)	3 (14)	11 (35)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Referral (%)					
Yes	0 (0)	3 (2)	1 (1)	2 (2)	2 (3)
No	70 (100)	123 (98)	72 (99)	84 (98)	69 (97)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Referral type (%)					
BBV & STI	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)
Drug health	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)
Other health	0 (0)	1 (33)	0 (0)	1 (50)	1 (50)
Other non-health	0 (0)	1 (33)	1 (100)	0 (0)	0 (0)
Peer based	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
More than one	0 (0)	1 (33)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Note: Age groups collected in Tasmania are not aligned to AGE10P in 2017. *Age groups aligned to AGE10P in 2018-2021. Indigenous status not collected in Tasmania 2017-2019.

B.8 Victoria

Description of NSP services in Victoria

Victoria is the second most populous state or territory in Australia, with ~6.7 million residents in 2021. NSP services operate through a wide range of service providers, including funded primary NSPs, community health services, hospital accident and emergency units, municipal councils, drug treatment agencies, youth organisations and participating pharmacies. There are 18 primary outlets, 204 secondary outlets, 443 pharmacies and 14 SDMs in Victoria. Services are provided through fixed site, mobile services, outreach and foot patrol, and SDMs supply injecting equipment at no cost to the consumer. Programs to facilitate access to take-home naloxone are available through 35 public sector NSPs (11 primary and 24 secondary) in Victoria. Non-identifiable client-level and service-level OOS data are collected at all primary and secondary NSP services in Victoria. Line item client OOS data are sent to Victorian Department of Health on a monthly basis. Health education/interventions and referrals are collected as a combined data item and Victoria does not currently collect data on drug injected or the Indigenous status of NSP attendees.

Table B.8.1 Needle and syringe distribution by public and pharmacy sector, 2011/12-2020/21

VIC	Public	%	Pharmacy	%	Total
2011/12	9,683,500	89%	1,206,475	11%	10,889,975
2012/13	10,244,250	90%	1,131,895	10%	11,376,145
2013/14	10,258,550	90%	1,078,602	10%	11,337,152
2014/15	10,413,900	91%	1,044,812	9%	11,458,712
2015/16	11,808,350	91%	1,103,818	9%	12,912,168
2016/17	11,799,550	91%	1,228,677	9%	13,028,227
2017/18	11,100,050	90%	1,284,560	10%	12,384,610
2018/19	12,620,750	93%	940,139	7%	13,560,889
2019/20	14,148,860	93%	1,018,191	7%	15,167,051
2020/21	11,432,700	92%	1,027,114	8%	12,459,814

Table B.8.2 NSP outlet type and method by public and pharmacy sector, 2017-2021

Victoria	2017	2018	2019	2020	2021
NSP outlet type (%)	n=400	n=407	n=674	n=660	n=679
Primary	16 (4)	16 (4)	16 (2)	17 (3)	18 (3)
Secondary	144 (36)	137 (34)	209 (31)	202 (31)	204 (30)
SDM	7 (2)	18 (4)	14 (2)	14 (2)	14 (2)
Pharmacy	233 (58)	236 (58)	435 (65)	427 (65)	443 (65)
NSP outlet method (%)					
<i>Public sector NSP[^]</i>	n=167	n=171	n=239	n=233	n=236
Fixed	156 (93)	151 (88)	223 (93)	214 (92)	217 (92)
Outreach/mobile	25 (15)	24 (14)	35 (15)	37 (16)	40 (17)
SDM free	7 (4)	18 (11)	14 (6)	14 (6)	14 (6)
SDM chute	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM cost	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Peer distribution	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Naloxone*	-- --	-- --	37 (16)	35 (16)	35 (16)
<i>Pharmacy sector (fixed)</i>	233 (100)	236 (100)	435 (100)	427 (100)	443 (100)

[^] Public sector NSPs may have more than one NSP outlet method

-- Not collected

* % denominator = primary + secondary


Figure B.8.1 Total number of NSP outlets by SA3 in 2021

Table B.8.3 Occasion of service-level data, 2017-2021

Victoria	2017	2018	2019	2020	2021
Client-level	n=749	n=634	n=750	n=576	n=350
Age (%)					
<18 years	0 (0)	1 (<1)	3 (<1)	1 (<1)	0 (0)
18-20 years	5 (1)	3 (<1)	2 (<1)	3 (1)	0 (0)
21-25 years	28 (4)	27 (4)	23 (3)	12 (2)	4 (1)
26-30 years	78 (10)	51 (8)	70 (9)	44 (8)	36 (10)
31-35 years	156 (21)	145 (23)	210 (28)	133 (23)	89 (25)
36-45 years	334 (45)	225 (35)	255 (34)	254 (44)	139 (40)
46+ years	124 (17)	162 (26)	152 (20)	117 (20)	77 (22)
Not reported	24 (3)	20 (3)	35 (5)	12 (2)	5 (1)
Aged <26	33 (4)	31 (5)	26 (3)	16 (3)	4 (1)
Gender (%)					
Male	580 (77)	463 (73)	549 (73)	435 (76)	254 (73)
Female	160 (21)	157 (25)	173 (23)	131 (23)	90 (26)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	9 (1)	14 (2)	28 (4)	10 (3)	6 (1)
Service-level					
Health education/intervention (%)					
Yes	344 (46)	245 (39)	298 (40)	319 (45)	157 (45)
No	402 (54)	389 (61)	452 (60)	257 (55)	193 (55)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Health education/intervention type (%)^					
BBV & STI	125 (36)	58 (24)	135 (45)	168 (53)	18 (11)
Drug health	8 (2)	4 (2)	7 (2)	2 (1)	13 (8)
Other health	15 (4)	75 (31)	60 (20)	34 (11)	91 (58)
Other non-health	0 (0)	0 (0)	0 (0)	1 (<1)	1 (1)
More than one	196 (57)	108 (44)	96 (32)	114 (36)	34 (22)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Note: Indigenous status and drug(s) injected are not collected in Victoria. Age groups collected in Victoria are not aligned to AGE10P. Referrals and health education/interventions are combined and reported as health education/interventions in the NSP NMDC.

B.9 Western Australia

Description of NSP services in Western Australia

Western Australia (WA) has the largest land area of Australia's eight states and territories and is the fourth most populous jurisdiction, with ~2.7 million residents in 2021. NSPs are operated by both government and non-government agencies and include needle syringe exchange programs which supply free sterile needles and syringes upon the return of used equipment. NSPs are operated through a combination of fixed-sites, outreach and mobile services. Health service based NSPs provide sterile injecting equipment at no cost through regional hospitals, and some public health units, community health centres, community drug services and other health services. Pharmacy based NSPs are operated on a commercial basis, while most SDMs operate on a cost-recovery basis with packs available for \$3 (2 SDMs have no cost). In Western Australia there are 19 primary outlets, 107 secondary outlets, 593 pharmacies and 8 SDMs. Programs to facilitate access to take-home naloxone are available through 15 public sector NSPs (14 primary and 1 secondary) in Western Australia. Non-identifiable client-level and service-level OOS data are collected by selected primary and secondary NSPs on a designated snapshot day on an annual basis in Western Australia. All NSP NMDC client-level and service-level data elements are collected.

Table B.9.1 Needle and syringe distribution by public and pharmacy sector, 2011/12–2020/21

WA	Public	%	Pharmacy	%	Total
2011/12	3,182,161	71%	1,270,829	29%	4,452,990
2012/13	3,502,135	73%	1,292,876	27%	4,795,011
2013/14	3,818,543	75%	1,286,760	25%	5,105,303
2014/15	4,048,932	74%	1,391,497	26%	5,440,429
2015/16	4,629,223	77%	1,386,095	23%	6,015,318
2016/17	4,583,785	79%	1,232,483	21%	5,816,268
2017/18	4,871,810	83%	1,017,615	17%	5,889,425
2018/19	5,338,373	84%	992,868	16%	6,331,241
2019/20	5,573,430	86%	926,922	14%	6,500,352
2020/21	4,772,606	85%	850,489	15%	5,623,095

Note: includes updated data for 2017/18 and 2018/19

Table B.9.2 NSP outlet type and method by public and pharmacy sector, 2017-2021

Western Australia NSP outlet type (%)	2017 n=671	2018 n=729	2019 n=728	2020 n=727	2021 n=727
Primary	19 (3)	19 (3)	17 (2)	19 (3)	19 (3)
Secondary	102 (15)	105 (14)	105 (14)	105 (14)	107 (15)
SDM	8 (1)	8 (1)	7 (1)	7 (1)	8 (1)
Pharmacy	542 (81)	597 (82)	599 (82)	596 (82)	593 (82)
NSP outlet method (%)					
<i>Public sector NSP[^]</i>	n=129	n=132	n=129	n=131	n=134
Fixed	108 (84)	112 (85)	112 (87)	114 (87)	116 (87)
Outreach/mobile	13 (10)	18 (14)	16 (12)	16 (12)	16 (12)
SDM free	1 (1)	1 (1)	2 (2)	1 (1)	3 (2)
SDM chute	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
SDM cost	7 (5)	7 (5)	5 (4)	6 (5)	5 (4)
Peer distribution	7 (5)	7 (5)	7 (5)	7 (5)	7 (5)
Naloxone*	-- --	-- --	14 (11)	14 (11)	15 (11)
<i>Pharmacy sector (fixed)</i>	542 (100)	597 (100)	599 (100)	596 (100)	593 (100)

[^] Public sector NSPs may have more than one NSP outlet method

-- Not collected

* % denominator = primary + secondary


Figure B.9.1 Total number of NSP outlets by SA3 in 2021

Table B.9.3 Occasion of service-level data, 2017-2021

Western Australia	2017	2018	2019	2020	2021
Client-level	n=126	n=202	n=173	n=184	n=165
Age (%)					
<20 years	0 (0)	5 (2)	4 (2)	0 (0)	0 (0)
20-29 years	22 (17)	29 (14)	17 (10)	19 (10)	27 (16)
30-39 years	32 (25)	44 (22)	47 (27)	54 (29)	50 (30)
40-49 years	46 (37)	79 (39)	64 (37)	77 (42)	56 (34)
50+ years	26 (21)	44 (22)	41 (24)	33 (18)	32 (19)
Not reported	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)
Aged <25 (%)	7 (6)	15 (7)	7 (4)	3 (2)	11 (7)
Gender (%)					
Male	84 (67)	139 (69)	107 (62)	108 (59)	111 (67)
Female	42 (33)	61 (30)	64 (37)	73 (40)	54 (33)
Other	0 (0)	1 (1)	2 (1)	3 (2)	0 (0)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Indigenous status (%)^					
Yes (Aboriginal or TSI or both)	22 (17)	36 (18)	42 (24)	48 (26)	40 (24)
No	102 (81)	156 (77)	121 (70)	134 (73)	119 (72)
Not reported	2 (2)	10 (5)	10 (6)	2 (1)	6 (4)
Drug injected (%)^					
Analgesics	37 (29)	58 (29)	42 (24)	50 (27)	29 (18)
Stimulants and Hallucinogens	65 (52)	127 (63)	106 (61)	123 (67)	106 (64)
Anabolic agents	7 (6)	10 (5)	4 (2)	5 (3)	10 (6)
Other	13 (10)	5 (2)	18 (10)	4 (2)	6 (4)
Not reported	4 (3)	2 (1)	3 (2)	2 (1)	14 (8)
Service-level					
Health education/intervention (%)^					
Yes	45 (36)	165 (82)	139 (80)	127 (31)	64 (39)
No	80 (63)	37 (18)	34 (20)	57 (69)	101 (61)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Health education/intervention type (%)^					
BBV & STI	19 (43)	103 (62)	45 (32)	80 (63)	40 (63)
Drug health	5 (11)	7 (4)	4 (3)	8 (6)	6 (9)
Other health	2 (5)	6 (4)	18 (13)	1 (1)	3 (5)
Other non-health	4 (9)	2 (1)	5 (4)	1 (1)	1 (2)
More than one	14 (32)	47 (28)	65 (47)	37 (29)	12 (19)
Not reported	0 (0)	0 (0)	2 (1)	0 (0)	2 (3)
Referral (%)^					
Yes	1 (1)	37 (18)	34 (21)	32 (17)	10 (6)
No	121 (96)	148 (73)	127 (79)	152 (83)	155 (94)
Not reported	4 (3)	17 (8)	0 (0)	0 (0)	0 (0)
Referral type (%)^					
BBV & STI	1 (100)	10 (27)	12 (35)	8 (25)	6 (60)
Drug health	0 (0)	2 (5)	5 (15)	11 (34)	2 (20)
Other health	0 (0)	9 (24)	13 (38)	10 (31)	0 (0)
Other non-health	0 (0)	0 (0)	3 (9)	2 (6)	2 (20)
Peer based	0 (0)	13 (35)	1 (3)	0 (0)	0 (0)
More than one	0 (0)	3 (8)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)

Glossary

Broad-level drug groups from the ABS Drugs of Concern Classification¹⁴ relevant to the NSP NMDC:

Analgesics

Broad-level drug group that includes the base-level drug groups of heroin, methadone, morphine and Subutex/buprenorphine.

Stimulants and Hallucinogens

Broad-level drug group that includes the base-level drug groups of amphetamine, methamphetamine (speed, crystal/ice, base) and cocaine.

Anabolic Agents and Selected Hormones

Broad-level drug group that includes the base-level drug groups of steroids, peptides, growth hormone and other PIEDs.

Other

Broad-level drug group that includes the base-level drug groups of Suboxone and 'Other (specified)'.